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I. General introduction
Stem Cell Differentiation within the Human Prostate Epithelium
Geert J.L.H. van Leenders and Jack A. Schalken
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Chapter I
Abstract
The phenotypic and biological characteristics o f prostate epithelial cell subpopulations are reviewed together 
with their implications for epithelial differentiation and prostate carcinogenesis. Keratin (K) expression analysis 
can differentiate between at least four prostate epithelial cell types. Basal cells express high K5, low  K18 
(K5++/18+) and a subgroup co-express K14 (K5++/14++/18+). Luminal cells express high K18 levels (K18++), 
while K5 (K5+/18++) is observed in focal cell clusters. Androgen-induced prostate regeneration in rats and in 
vitro human studies indicate that subgroups o f  basal cells (K5++/14++/18+) are progenitors o f intermediate 
(K5/18) and terminally differentiated cells (K18++), which is in agreement with the high proliferative activity in 
basal cells and the occurrence o f  apoptosis particularly in luminal cells. Prostate cancer is composed o f 
exocrine, neuro-endocrine and intermediate cells. In androgen-deprived tumours the proportion o f  intermediate 
and neuro-endocrine cells is enriched suggesting these cells are androgen-independent for their survival/ 
renewal and might govern androgen-independent expansion o f  prostate cancer. We conclude that evidence is 
accumulating for a stem cell function o f  basal cells in the human prostate epithelium. Although putative stem  
cells are absent in prostate carcinoma, intermediate cells might by progenitors o f  prostate carcinogenesis and 
targets for androgen-independent prostate cancer progression.
Introduction
The maintenance of human tissue integrity is governed by the proliferation of stem cells, 
identified within rapidly proliferating organs such as bone marrow, intestinal tract and 
squamous epithelium (1,2). Stem cells are characterized by a relatively undifferentiated state 
and have a high proliferative capacity and a long life span. After mitosis, they give rise to an 
intermediate cell population that modulates advanced tissue development by transient 
proliferation, while undergoing maturation towards a terminally differentiated state. 
Corresponding stem cell lineages have been proposed within the human prostate epithelium
Within the human prostate epithelium, two cell types can be discriminated 
morphologically. High-columnar luminal cells constitute the exocrine compartment of the 
prostate epithelium, secreting Prostate Specific Antigen (PSA) and Prostate Acid Phosphatase 
(PAP) into the glandular lumina. Luminal cells express high levels of the androgen-receptor 
(AR) and are dependent on androgens for their survival. The basal cell compartment is 
believed to harbour stem cells of the entire prostate secretory epithelium. Basal cells express 
low/ undetectable levels of AR and are independent of androgens for their survival (4). By 
immunophenotypic characterization of the human prostate epithelium, researchers have 
identified additional cell populations. First, neuro-endocrine cells are dispersed within the 
prostate epithelium. Although the function of neuro-endocrine cells is largely unknown, they
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might induce proliferation of adjacent cells modulated by paracrine secretion of neuro­
peptides like chromogranin A and synaptophysin (5). A fourth distinct cell population is 
immunophenotypically characterized as an intermediate between basal and luminal cells.
In 1989, Isaacs and Coffey postulated a hierarchic stem cell model for the prostate 
epithelium (3). Accordingly, stem cells of the entire prostate epithelium are localized within 
the basal cell compartment. By asymmetric cell division, they give rise to one stem cell copy 
(self renewal) and one progenitor cell that is destined to amplify the development of the 
epithelium. After a limited number of cell cycles, a state of terminal differentiation is attained 
and cells will finally undergo apoptosis. During expansion, amplifying cells translocate 
towards the luminal cell layer and gain either exocrine or neuro-endocrine characteristics. 
Interestingly, the stem cell concept has gained increasing interest in the study of prostate 
carcinogenesis and is being considered in the development of novel treatments for prostate 
cancer. Prostate cancer is initially regarded as an androgen-dependent disease as therapeutic 
androgen-ablation induces massive apoptosis of malignant cells and clinically leads to tumour 
regression. However, after a remission period for up to several years, tumours usually 
progress despite low circulating androgen levels. Currently, no therapeutic options are 
available for the treatment of androgen-independent prostate cancer.
In this study, differential immunophenotypic and cell biological characteristics of 
epithelial cell populations are analysed in relation to stem cell models in the human prostate. 
Furthermore, we discuss the implications of epithelial cell differentiation for prostate 
carcinogenesis and tumour progression.
Keratin Expression Discriminates Four Prostate Epithelial Cell Types
Keratins belong to the group of intermediate-filament proteins that form part of the 
cytoskeleton by heterodimeric interaction and polymerization (6). Epithelial cells express 
subgroups of keratins enabling discrimination between basal and luminal localization. As in 
all simple epithelia, luminal cells in the human prostate express high levels of K8 and 18 
(K8++/18++) (7-9). Basal cells were originally identified by their expression of K5 and 14, 
while basal cells also have low levels of K8 and 18 (K5++/14++/18+) (10-12). The analysis of 
keratins in epithelial differentiation has further identified two additional cell types with an 
intermediate, basal-luminal phenotype in the prostate. The first cell group was characterized 
by co-localization of K5 and K18 (K5+/18++) within clusters of luminal cells, while a
9
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subpopulation of basal cells shows expression of K5 in the absence of K14 (K5++/18+) (12­
16). Figure 1 (Appendix).
Keratin expression analysis has become an important methodological tool for tracking 
basal, intermediate and luminal cells in the biological characterization of prostate epithelium. 
Expression of K5 in luminal cells and K14 in basal cells identifies prototypes of intermediate 
and putative stem cells in the prostate epithelium. Using double-staining with 34PE12 (anti- 
K1, K5, K10, K14), Bonkhoff et al. identified 34pE12-positive cells expressing PSA within 
the luminal epithelium (17). This observation is indicative of a hierarchic relationship 
between intermediate and differentiated exocrine cells, suggesting that a subgroup of 
intermediate cells develops towards exocrine, luminal cells. The keratin expression of neuro­
endocrine cells is complex and not yet fully elucidated. Separate analysis of keratins in neuro­
endocrine cells suggests that neuro-endocrine differentiation appears early, at about the same 
time in classic basal cells (K5++/14++/18+), intermediate (K5/18) and in differentiated cells, 
again indicating a hierarchic relation between epithelial subpopulations (17,18).
Basal Cells are Progenitors of Luminal Epithelium
Immunofluorescent double- and triple-staining techniques enable unequivocal discrimination 
of complex keratin expression patterns, and are thus useful tools to study epithelial 
differentiation in vitro (12,19). Two growth phases are identified in primary epithelial cell 
cultures of the prostate. After adherence and initial expansion, prostate epithelial cell cultures 
are predominantly composed of cells with a basal phenotype (K5++/14++/18+). Upon extension 
and confluence of this basal-like layer, glandular buds appear on top of the monolayer, 
typically composed of cells with intermediate (K5/18) and luminal immunophenotypes 
(K8++/18++) (12,19,20). Furthermore, keratin expression has been applied to study epithelial 
differentiation in rodents. Androgen-deprivation induces massive apoptosis of the luminal 
epithelium in rats, while the basal cell layer largely remains unaffected (13). However, after 
re-administering androgens, the luminal epithelium expands towards its original state, while 
intermediate cells prominently appear within the luminal cell compartment.
These results support the classic stem cell concept and indicate that a subgroup of 
basal cells (K5++/14++/18+) reveals stem cell characteristics of the entire prostate epithelium. 
Asymmetric mitosis of this cell population results in a larger pool of progenitor/ intermediate 
cells that by transient proliferation gives rise to an expansion of epithelial ductal structures.
10
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During maturation, intermediate cells obtain either exocrine or neuro-endocrine 
characteristics, while K5 and K14 are simultaneously down-regulated and K8 and K18 over­
expressed. Figure 2.
Figure 2. Classic stem cell model of the human prostate epithelium A stem cell population 
(K5++/14++/18+) in the basal cell layer gives rise to intermediate basal cells (K5++/18+). By 
proliferation and translocation a second intermediate cell type (K5+/18++) arises in the 
luminal cell layer. This intermediate cell population transiently proliferates and shows 
maturation (K18++). During differentiation, intermediate cells either obtain exocrine or 
neuro-endocrine characteristics. Terminal differentiation (TD) occurs in post-mitotic cells.
Cellular Homeostasis in the Prostate Epithelium
Epithelial homeostasis results from a steady state equilibrium of cellular apoptosis and 
proliferation. Within the prostate epithelium, apoptotic and proliferative activity are 
discordant in the basal and luminal cell compartment. The highest rate of cell death in the 
prostate epithelium is observed within the luminal cell layer, while apoptosis occurs at a low 
incidence in basal cells (21). Several molecular mechanisms appear to protect basal cells from 
apoptosis. First, senescence of basal cells is extended by telomerase activity. Senescence is 
associated with progressive shortening of (chromosomal-) telomeres and upon a critical 
telomere length, activation of the apoptotic cascade will result in cell death. Reduction in 
telomere length is prohibited by telomerase, a riboprotein complex that maintains telomeres,
11
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and thus the occurrence of apoptosis in normal cells can be delayed. Accordingly, an 
important role in malignant transformation has been proposed, and indeed telomerase activity 
is found in several human cancers (22). Within the prostate epithelium, telomerase activity is 
high in basal cells and low in the luminal epithelium, indicating that luminal cells are more 
sensitive to apoptosis (23). Furthermore, expression of the oncoprotein bcl-2 provides 
protection from apoptotic stimuli. Expression of bcl-2 is restricted to the basal cell 
compartment of the prostate. The absence of bcl-2 in the luminal epithelium predisposes 
exocrine as well as neuro-endocrine cells to undergo apoptosis (18,24,25).
Various immunohistochemical techniques are available for the detection of 
proliferating cells in situ. The monoclonal antibody MIB-1 reacts with the antigen Ki-67, 
which is specifically expressed in late G1, S, G2 and M phase of the cell cycle (for review 
Scholzen et al. (26)). In contrast to preferential occurrence of apoptosis in the luminal 
epithelium, Ki-67 is predominantly expressed in the basal cell compartment (27). The 
proliferative capacity of luminal exocrine cells is low, while neuro-endocrine cells are 
considered post-mitotic (28). Progression through the cell cycle is governed by activated 
complexes of cyclins and cyclin-dependent kinases (cdk), and can be inhibited by binding of 
cdk inhibitors such as p21/cip1/waf and p27/kip1. The cdk inhibitor p27/kip1 preferentially 
inactivates the cyclin E/cdk2 complex, thereby preventing cell cycle progression from G1 to S 
phase. Within the non-malignant prostate epithelium, the vast majority of luminal cells 
express high levels of p27/kip1, which is in agreement with their post-mitotic state of terminal 
differentiation. Expression of p27/kip1 in a subgroup of basal cells is further associated with 
the predominantly quiescent state of stem cells. Interestingly, De Marzo et al. showed that 
both subgroups of basal cells, and cells with an intermediate location between the basal and 
luminal cell compartment, lacked expression of p27/kip1 (29). Removal of the cell-cycle 
block in these cells potentially delineates a transiently proliferating cell group in the prostate 
epithelium. The preferential localization of proliferation in basal cells and apoptosis in 
luminal cells is consistent with the assumption that basal cells are progenitors of the luminal 
epithelium. The absence of p27/kip1 in intermediate cells supports their role of transiently 
proliferating/ amplifying cells.
Topographic reversal of proliferative activity is observed in androgen-deprived and 
regenerative prostate tissue. As mentioned earlier, castration leads to massive cell loss within 
the rodent luminal prostate epithelium. However, re-administration of androgens induces an 
enhanced proliferative response, particularly in the luminal cell compartment, resulting in 
regeneration of the prostate epithelium (30,31). While Ki-67 expression is usually localized
12
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within basal cells under the normal androgenic state in humans, it predominates in luminal 
cells six months after androgen-deprivation (32). These results have led to an alternative 
theory about the histogenic development of the prostate epithelium, in which both the basal 
and luminal epithelium are derived from distinct progenitor cells. Nevertheless, in our opinion 
the topographic reversal of proliferation after androgen-withdrawal does not exclude the stem 
cell model of Isaacs and Coffey. Androgen-deprivation leads to apoptosis of androgen- 
dependent cells that are almost exclusively localized within the luminal cell layer. The vast 
majority of androgen-dependent cells are post-mitotic, terminally differentiated cells. 
Androgen-withdrawal therefore results in massive loss of post-mitotic luminal cells, leading 
to a relative increase in progenitor cells that have not yet reached terminal differentiation and 
still have proliferative capacity i.c. the intermediate cell population. Although this cell 
population seems independent of androgens for survival/ self renewal, it is androgen-sensitive 
and responds to androgens by proliferation/ expansion.
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Figure 3. Proliferative Inflammatory Atrophy (PIA). A, B Cubical, hyperchromatic luminal 
cell layers encompass slit-like gland lumina, while the surrounding stroma is infiltrated by 
lymphocytes. C Regular nuclear expression of Ki-67 (arrow-heads) indicates high 
proliferative activity within the luminal cell layer.
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Homeostasis in Atrophic Glandular Epithelium
Within the human prostate epithelium, two types of atrophy are discerned. The first type is 
associated with androgen-deprivation and occurs generally in all epithelial glands. The second 
type is localized and not associated with androgen-withdrawal. Paradoxically, focal atrophic 
glands reveal high proliferative activity in the luminal epithelium, which is not paralleled by 
an increase in apoptosis (33,34). The frequent association of a chronic inflammatory reaction 
with atrophic glands led De Marzo et al. to propose the term ‘Proliferative Inflammatory 
Atrophy’ (PIA) for these lesions (35). Figure 3. This group further characterized luminal cells 
in PIA lesions as intermediate cells. In addition to a high proliferative activity and an absence 
of p27/kip1, luminal cells in PIA lesions are protected from apoptosis because they strongly 
express bcl-2. Interestingly, PIA lesions show topographic coherence with and morphological 
transition to Prostate Intraepithelial Neoplasia (PIN), which is regarded as a precursor lesion 
of prostate carcinoma (36).
Peptide Growth Factor Receptors
Stromal-epithelial interactions govern proliferation and differentiation of the prostate 
glandular epithelium (37). The stromal cell compartment expresses AR, and stimulation with 
dihydrotestosteron (DHT) leads to the paracrine release of several peptide growth factors. The 
receptors for most ligands are predominantly localized within the basal cell layer, e.g. 
Epidermal Growth Factor Receptor (EGFR), HER-2/ neu receptor, and Hepatocyte Growth 
Factor receptor c-met (38-41). Activation of these receptors can induce variable cell biological 
responses in vitro, including proliferation, morphogenesis and migration. Therefore, for 
survival and self renewal, basal cells appear to be dependent on growth factors rather than on 
circulating androgens.
Novel Prostate Stem Cell Markers
Over the last decade, more potential epithelial stem cell markers have been identified in the 
prostate, including pp32, Prostate Stem Cell Antigen (PSCA) and p63. While the function and 
cellular localization of these antigens are still relatively unknown, their involvement in self 
renewal and/or tissue development suggests a role in stem/ progenitor cell biology.
14
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pp32
The nuclear phosphoprotein pp32 was initially discovered in neoplastic B-cells (42). The 
protein pp32 is moreover localized in intestinal crypts that harbour the stem cell compartment 
of the digestive tract epithelium. Within the prostate epithelium, pp32 is predominantly 
expressed in budding tips at the gland’s periphery, which have been proposed as stem cell 
areas capable of self renewal in embryonic and adult tissues (43). pp32 inhibits oncogene- 
mediated transformation in vitro and thereby protects putative stem cells from malignant 
degeneration. Although pp32 was initially reported to be highly expressed in prostate 
carcinoma, Kadkol et al. recently showed high levels of two related genes, pp32r1 and 
pp32r2, which are approximately 90% identical to pp32 versus low levels of pp32 in prostate 
carcinoma (44,45).
Prostate Stem Cell Antigen
PSCA is a prostate-specific cell surface antigen originally identified by its high expression in 
the LAPC-4 prostate cancer xenograft model, using representational display analysis. PSCA 
is expressed by a subset of basal cells in the normal prostate epithelium, whereas luminal cells 
are negative. Based on its homology to Stem Cell Antigen 2, which is involved in 
haematopoiesis by preventing apoptosis in immature thymocytes, PSCA is putatively 
expressed in stem/ progenitor cells of the human prostate epithelium (46).
The nuclear protein p63, a homologue of the p53 tumour suppressor gene, encodes for six 
isotypes that either transactivate p53 reporter genes or act as p53-dominant negatives (47). 
p63 is expressed in the basal cell compartment of squamous epithelia, and in mammary, 
salivary and prostate gland tissue. p63-deficient mice show agenesis of the prostate gland and 
severe defects in the development of other organs, suggesting that p63 is necessary for stem 
cell maintenance. In the adult prostate, neither luminal exocrine nor neuro-endocrine cells 
express p63. Interestingly, co-localization of basal keratins and p63 is found in most prostate 
glands, while a minority (1-5%) of p63-positive cells do not stain with 34PE12 (48). This 
might indicate that p63 is not only a marker of putative stem cells but also of progenitor cells 
in the prostate.
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Cellular Composition of Prostate Cancer
At least three different cell populations can be discriminated in prostate carcinoma. The vast 
majority of malignant cells are characterized as luminal cells by their expression of K8, K18, 
AR and PSA. It was therefore initially believed that malignant transformation of the prostate 
epithelium originated from this cell type (7,8,10,11). Scattered neuro-endocrine cells are 
frequently present in prostate carcinoma (49). Although the histogenic origin of neuro­
endocrine cells in normal prostate epithelium is not yet fully elucidated, several physiological 
and pharmacological agents have the capacity to induce neuro-endocrine differentiation in 
malignant cells in vitro. Serum-depletion of the androgen-dependent prostate cancer cell line 
LNCaP, as well as stimulation with Epi, Fsk, interleukin 1 or 6, results in reversible 
acquisition of neuro-endocrine features, such as development of dendrite-like extensions, 
expression of chromogranin A and abrogation of proliferative activity (50-52). Furthermore, 
Verhagen et al. showed co-localization of K5 and K18 in primary prostate carcinoma, while 
expression of K14 has never been recognized (14). Therefore, intermediate cells participate in 
prostate carcinoma in contrast to the putative stem cell population. This finding might further 
explain the anecdotal findings of reactivity of ‘basal’ cell marker 34PE12 in prostate cancer 
metastasis (53,54).
Basal cell characteristics are generally sparse in androgen-dependent prostate 
carcinoma and can only be observed in a minority of malignant cells. Interestingly, androgen- 
deprived survival of prostate cancer seems to select for cells with a ‘basal’ phenotype. 
Enhancement of K5 and chromogranin A in androgen-deprived tumours indicates that 
intermediate and neuro-endocrine cells are both androgen-independent for their survival 
(55,56). The enrichment of intermediate and neuro-endocrine cells continues to occur in 
androgen-independent tumour progression. In addition, up-regulation of ‘basal’ cell receptors 
EGFR and HER-2/neu might provide molecular biological pathways that are involved in 
hormone-escaped prostate tumours (57,58).
Epithelial Cell Hierarchy and Prostate Carcinogenesis
Unravelling of epithelial hierarchy in the normal prostate epithelium has important 
implications for the understanding of malignant transformation and androgen-independent 
progression of prostate cancer. Like other malignancies, prostate carcinoma is regarded as a 
clonal expansion of a malignantly transformed cell population. This fundamental concept
16
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implies that the heterogeneous cell population found in prostate cancer is derived from one 
initially transformed target cell. Proliferation and remaining ability to differentiate of this cell 
group can explain the existence of phenotypically distinct cell types in prostate cancer. 
Clearly, progressive acquisition of genetic changes further leads to subclonal expansion of the 
cancer process, and explains the heterogeneous appearance of prostate carcinoma. According 
to the putative stem cell model of epithelial differentiation, Verhagen et al. postulated that an 
amplifying cell in fact undergoes malignant transformation and therefore this cell type would 
play a pivotal role in prostate carcinogenesis (14). Although the sparse observation of 
intermediate cells in normal prostate epithelium seems in conflict with the common incidence 
of prostate cancer, strong evidence exists that PIA lesions are enriched for intermediate cells 
(35). These lesions often reveal topographic coherence with prostate carcinoma and 
morphological transitions to PIN (36). Therefore, several groups proposed atrophic glandular 
epithelium as the source of precursor cells in prostate tumours (33,35).
Therapeutic androgen-deprivation abrogates most exocrine, terminally differentiated 
prostate cancer cells, but affects neither intermediate nor neuro-endocrine cells. This indicates 
that both cell types are independent of androgens for their survival. In concordance with the 
cell biological hypothesis of prostate carcinogenesis, intermediate cells therefore seem 
androgen-independent at the time of initial malignant transformation. Further expansion of 
this cell group despite low androgen-levels would finally result in androgen-independent 
progression of prostate cancer. Figure 4. Evidence is accumulating that the AR-mediated 
pathways are still activated in prostate cancer, albeit in a ligand-independent manner (58). 
Recruitment of other signalling pathways that finally integrate with the AR signalling 
provides a molecular explanation of androgen-independent tumour progression.
It is intriguing to relate molecular characteristics of intermediate cells to androgen­
independent survival. Activation of tyrosine-kinase receptors such as HER-2/neu has been 
implicated in androgen-independent progression of prostate cancer because they might cross­
link the AR pathway (58). Peptide growth factor receptors are predominantly localized within 
the basal cell layer. Currently, the expression profile of growth factor receptors is specifically 
analysed in intermediate cells in normal and malignant prostate epithelium. We hypothesize 
that peptide growth factor receptors are physiologically expressed in intermediate cells. 
Activation of peptide growth factor signalling pathways in androgen-independent prostate 
cancer is therefore associated with the selection and adaptation of intermediate cells resulting 
in the expansion of a cancer cell population that is independent of androgens ab origine.
17
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Androgen-dependent cancer
Exocrine differentiation
Androgen-independent cancer
Exocrine differentiation
*
/
\
Neuro-endocrine differentiation Neuro-endocrine differentiation
Figure 4. Epithelial cell model for prostate carcinogenesis. Intermediate cells are target cells 
for malignant transformation of the prostate epithelium, retaining their capacity to show 
either exocrine or neuro-endocrine differentiation. The final step of terminal, exocrine 
differentiation is believed to be dependent on androgens. In androgen-independent prostate 
cancer, terminal exocrine differentiation is abolished, which leads to relatively increased 
numbers of intermediate and neuro-endocrine cells.
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Scope ofthe thesis
II. Scope of the thesis
The aim of the present study is the characterization of intermediate cells in the human prostate 
epithelium, which may contribute to a better understanding of the cellular kinetics involved in 
normal epithelial differentiation and prostate carcinogenesis. This is addressed in the 
following chapters:
Chapter III: A technique for the identification of intermediate cells in prostate tissue and its 
derived primary cell cultures is developed. The existence of two intermediate cell types was 
disclosed within the prostate epithelium, while strong evidence was gained for a hierarchic 
stem cell concept for the entire prostate epithelium.
Chapter IV: The occurrence of intermediate cells in human prostate cancer metastases is 
studied and support for their androgen-independent nature is gained, as is reflected in 
respective cell lines.
Chapter V: The receptor c-met is searched for in intermediate cells in normal and malignant 
prostate epithelium, providing an explanation for the occurrence of molecular pathways 
inherent to basal cells in prostate carcinoma.
Chapter VI: Proliferative Inflammatory Atrophy is analysed as a histological lesion in which 
intermediate cells are highly enriched, facilitating the future study of intermediate cells and 
supporting their involvement in prostate carcinogenesis.
Chapter VII: a2-Integrin is studied as a novel marker of intermediate cells using cDNA 
micro-array analysis. The subsequent cell biological implications are discussed.
Chapter VIII: The implications of this thesis for the role of intermediate cells as progenitor 
cells of prostate cancer are discussed, including targets of its androgen-independent 
progression. Potential therapeutic consequences of this cell biological concept are elucidated.
23
Chapter II
24
Demonstration of Intermediate Cells during Human Prostate 
Epithelial Differentiation In Situ and In Vitro using Triple- 
Staining Confocal Scanning Microscopy
Geert J.L.H. van Leenders, Henry B.P.M. Dijkman,
Christina A. Hulsbergen-van de Kaa, Dirk J. Ruiter, Jack A. Schalken
III.
Lab Invest 2000; 80: 1251-1258
25
Chapter III
Abstract
In human prostate epithelium, the basal cell layer putatively contains progenitor cells o f the secretory epithelium 
and is characterized by expression o f keratins (K) 5 and 14, while luminal cells represent the secretory 
compartment o f the epithelium expressing K8 and 18. In order to identify intermediate cell stages in the prostate 
epithelium a technique was developed for the simultaneous analysis o f K5, 14 and 18. Non-malignant prostate 
tissue and primary epithelial cultures were immunohistochemically characterized using a triple-staining 
technique with antibodies towards K5, K14 and K18. Antibodies towards K18 and K5 were conjugated directly 
with fluorochromes Alexa™ 488 and 546. K14 was visualized indirectly with streptavidin-Cy5. Keratin 
expression was analysed by confocal scanning microscopy. We found that basal cells either expressed 
K5++/14++/18+ or K5++/18+. The majority o f luminal cells expressed K18++, but co-localization o f K5+/18++ was 
focally recognized. Epithelial monolayer cultures predominantly revealed the basal cell phenotype 
K5++/14++/18+, whereas intermediate subpopulations expressing K5+/14+/18++ and K5+/18++ were also 
identified. Upon confluence, differentiation was induced as multicellular gland-like buds and extensions became 
evident on top o f the monolayer. These structures were composed o f K18++- and K5+/18+-positive cell clusters 
surrounded by phenotypically basal cells. Few multicellular structures and cells in monolayer showed exocrine 
differentiation (PSA+), but expression o f chromogranin A and serotonin were absent. In conclusion, 
simultaneous analysis o f K5, K14 and K18 identifies two intermediate cells characterized as basal K5++/18+- 
and luminal K5+/18++- expression. In vitro, basal cells resembling K5++/14++/18+ are progenitors o f luminal 
cells (K18++).
Introduction
Within the secretory epithelium of the human prostate morphologically basal and luminal 
cells can be discriminated. The basal cell layer is believed to contain the stem cell population 
of the prostate epithelium (1-4). This stem cell population has a long life span and a large 
proliferative capacity. Isaacs and Coffey described a model in which stem cells on self 
renewal give rise to a transiently proliferating (TP)/ amplifying cell population that has a 
shorter life span and limited cyclic activity (5). This cell population is situated in the basal as 
well as the luminal cell layer and finally differentiates into exocrine or neuro-endocrine cells 
(6,7). Exocrine differentiation occurs in the majority of the luminal cells and is identified by 
expression of Prostate Specific Antigen (PSA). Neuro-endocrine cells are dispersed in the 
prostate epithelium and secrete neuropeptides like chromogranin A and synaptophysin. 
Recently, the TP/ amplifying cells have gained attention because they indicate the existence 
of a hierarchic relationship in the prostate epithelium and putatively play a role in neoplastic 
diseases.
Expression of keratins (K) has gained validity as a marker for cell lineage 
differentiation. Keratins belong to the group of intermediate filament proteins that form the
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cell skeleton by heterodimeric interaction (8). Epithelial cells express subgroups of keratins, 
enabling discrimination between basal and luminal localization. As in all simple epithelia, 
luminal cells in the human prostate express K8 and 18 (9-11). Basal cells are originally 
identified by their expression of K5 and 14, but K8 and 18 are present in at least a subset of 
them (12,13). A few studies also report co-localization of “basal” and “luminal” keratins in 
the luminal cell layer, interpreted as an intermediate phenotype in the prostate (3,14). These 
intermediate cells are candidates for the TP/ amplifying cells in the prostate. The keratin 
expression of neuro-endocrine cells is complex and not yet fully elucidated (6,15).
The cellular origin of prostate cancer development requires an understanding of 
epithelial differentiation. Prostate carcinoma is clinically described as an androgen-dependent 
disease and therapeutic withdrawal of androgens usually results in tumour regression. 
However, the disease finally progresses to an androgen-independent status in which it no 
longer responds to androgen blockade and no therapeutic options are available. To understand 
the cell biological aspects of this, evaluation of keratin expression is useful because it 
identifies the epithelial composition of prostate cancer. In general, prostate carcinoma has a 
luminal cell phenotype (PSA+, K18+); it was therefore postulated that malignant 
transformation of this cell type results in the origin of prostate carcinoma (9,11,13,16). 
Several studies, however, also describe the presence of basal cell characteristics in prostate 
carcinoma (14,17,18). Interestingly, an increase of basal markers is associated with androgen­
independent tumour progression (19,20). This led to the hypothesis that an alternative cell 
type is involved in carcinogenesis of the prostate that is the amplifying cell (5,14). 
Investigation of the stem cell lineage in secretory prostate epithelium is therefore crucial to 
understand the role of TP/ amplifying cells in carcinogenesis and cancer progression in the 
prostate.
Identification of the cell biological characteristics of intermediate, TP/ amplifying 
cells has been hampered by the lack of a technique that can adequately visualize “basal” and 
“luminal” markers in the same cell. In this study, we describe a method for the simultaneous 
analysis of K5, 14 and 18. We directly demonstrate the existence of intermediate cell stages in 
normal human prostate epithelium and provide a cell culture model for the study of its 
differentiation.
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Materials and Methods
Tissue collection and cell culture
Tissue samples were obtained from 18 patients undergoing radical prostatectomy for prostate 
carcinoma. All patients gave informed consent for use of the specimens for research purposes. 
Immediately after surgery, fresh tissue was removed and frozen in N2. For cell culture, fresh 
tissue was aseptically dissected from the prostate peripheral zone using a skin biopsy punch (5 
x 15 mm) and transported in Dulbecco’s Modified Eagle Medium supplemented with 20% 
foetal calf serum, penicillin (100 U/ml), streptomycin (100 ^g/ml), and amphotericin B (2.5 
^g/ml). Three sections of the punch biopsy were removed for histopathological analysis. 
Tissue samples containing malignancy were excluded from this study. The specimens were 
minced into 1 mm-pieces, seeded in culture flasks (25 cm2), and covered with fresh medium. 
The explant cultures were maintained in a humidified incubator (37°C; 95%O2; 5%CO2). 
After outgrowth of the cells, culture medium was changed to Keratinocyte Serum-Free 
Medium (GibcoBRL, Paisley, UK), provided with KSFM supplement (insulin, epidermal 
growth factor, fibroblast growth factor), bovine serum albumin (BSA; 2.5 mg/ml), transferrin 
(2.0 p,g/ml) and minimal essential aminoacids (1%) (21). Confluent cell cultures were 
detached with trypsin/EDTA solution (0.05%/ 0.02%), washed, and subsequently grown in 
75-cm2 culture flasks. For characterization, cells (passage 2-6) were seeded on 8-wells TC 
Chamber Slides (GibcoBRL) at a density of 2.0-4.0 x 104 cells per well in KSFM medium. 
The culture media were refreshed every 3 to 4 days. After 1 to 2 weeks, the cell cultures were 
analysed using immunohistochemical techniques.
Direct antibody labelling
The antibodies RGE53 (K18) and RCK103 (K5) were directly labelled with fluorochrome 
dyes using Alexa™ 488 and Alexa™ 546 protein labelling kits (Molecular Probes, Eugene, 
OR, USA) according to the manufacturer’s guide. Table 1. Briefly, 1.0 mg of purified 
antibody was dissolved in 0.5 ml phosphate buffered saline (PBS) and provided with 50 ^l 
sodium bicarbonate (1 M). The antibody solutions reacted for 1 hour with succinimidyl esters 
of Alexa™ 488 (RGE53) and Alexa™ 546 (RCK103) carboxylic acid. Reactions were 
blocked by the addition of 17 ^l and 15 ^l hydroxylamine, respectively. After incubation for 
30 and 15 min, the labelled antibody was separated from the unincorporated dye using a resin 
column. The antibody concentration and labelling efficiency were analysed by 
spectrophotometry. The labelling efficiencies of RGE53 and RCK103 were 6.5 (optimal
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labelling, 4-9) and 3.6 (optimal labelling, 2-7), respectively. The labelling procedure was 
performed in the dark at room temperature (r.t.).
Table 1. Keratin antibodies and labelling specificities
Antibody Species Subtype Specificity Labelling Absorption Emission Colour
RGE53 Mouse IgG1 K18 Alexa 488 direct 494 nm 519 nm Green
RCK103 Mouse IgG1 K5 Alexa 546 direct 558 nm 573 nm Red
RCK107 Mouse IgG1 K14 Cy5 indirect 649 nm 670 nm Blue*
* While Cy5 labelled K14 generates a red fluorescent signal, this is depicted as a blue colour for distinction with 
the red signal of Alexa 546.
Triple-staining procedure
Cell culture slides and 4 p,m cryostat sections of prostate samples were fixed in acetone for 10 
minutes at -20°C and air-dried for 2 hours. The slides were incubated with undiluted RCK107 
antibody (K14) for 60 min. After washing in PBS, slides were incubated with biotinylated 
sheep anti-mouse Ig (1:100) for 30 min and conjugated with streptavidin-Cy5 (1:20) for 30 
min. Free binding sites were blocked with 10% normal mouse serum during 30 min. After 
extensive washing, slides were incubated with directly labelled RGE53 (20 ^g/ml) and 
RCK103 (5 ^g/ml) for 1 hour. Dilutions were made in PBS/1%BSA. All incubations were 
performed in the dark at r.t. The slides were mounted with fluorescent mounting medium 
(DAKO, Glostrup, Denmark) and analysed using confocal laser scanning microscopy 
(Confocal System LEICA TCS NT, Leica, Wetzlar, Germany).
Labelling apoptotic cells
The localization of apoptotic cells was determined using an antibody to activated caspase-3 
(PharMingen, San Diego, CA, USA) (22,23). Acetone-fixed, air-dried cell cultures were 
incubated with activated caspase-3 antibody (1:100) at 37°C for 1 hour. After washing in 
PBS, cultures were incubated with 1:200 goat anti-rabbit Ig labelled with Alexa™ 594 
(Molecular Probes) and RGE53 directly labelled with Alexa™ 488 for 1 hour at r.t.
Immunohistochemistry
Exocrine and neuro-endocrine differentiation was analysed using antibodies to PSA, 
chromogranin A and serotonin (DAKO). After acetone fixation and pre-incubation with 10% 
normal swine serum for 30 min, slides were incubated with antibodies for PSA (1:250), 
chromogranin A (1:1000), or serotonin (1:1000) for 1 hour at 37°C. After washing in PBS, the
29
Chapter III
cultures reacted with swine anti-rabbit Ig labelled with alkaline phosphatase (1:25) for 1 hour 
at r.t. Antibodies were visualized after incubation with alkaline phosphatase substrate (Vector 
Red; Vector Laboratories, Burlingame, CA, USA) for 20 min and counterstained with 
hematoxylin.
Results
Analysis o f  keratin expression using confocal laser scanning microscopy
Analysis of keratin expression using immunofluorescence and confocal laser scanning 
microscopy (CLSM) enables the simultaneous detection of K5, 14 and 18 in a single cell. 
Each labelled keratin produces a different fluorescent signal that is depicted as a specific 
colour. Expression of K5 is represented by red, K14 by blue, and K18 by green. It should be 
emphasized that K14 labelled with Cy5 originally generates a red fluorescent signal (670 nm) 
that is depicted by a blue colour for image analysis; this allows distinction between K14 and 
the red signal of Alexa 546 labelled K5 (573 nm). Hybrid colours identify co-expression of 
keratins. Co-localization of red (K5) and green (K18) is depicted as yellow (K5/18), and a 
pink/purple colour (K5/14) represents expression of red (K5) and blue (K14). Simultaneous 
perception of red (K5), green (K18), and blue (K14) produces a white (K5/14/18) hybrid 
colour.
Keratin expression in situ
At least four different cell types were distinguished in the human secretory prostate 
epithelium by their pattern of keratin expression. The majority of the luminal cells strongly 
expressed K18 (K18++), but single cells and cell clusters showed co-expression of K5 and 18 
(K5+/18++). K18 expression was weak in the basal cell layer. All basal cells strongly 
expressed K5 (K5++/18+), and a subpopulation was also positive for K14 (K5++/14++/18+). 
Figure 1 (Appendix).
Cell culture morphology
After adherence, epithelial cells proliferated and formed cell clusters that grew in a 
monolayer. The morphology of these cells varied from small angular cells with scant 
cytoplasm to large round cells with abundant cytoplasm. A few cells had multiple cytoplasmic 
neurite-like extensions and were situated either within or on top of the monolayer. After
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confluence of cell clusters, multicellular gland-like buds and extensions were formed on top 
of the monolayer. In the beginning, one to three rounded cells were situated above the plane 
of the monolayer. Within one day buds were formed with a maximal height of 30 p,m that 
often made connection by multicellular extensions. Figure 2. No lumina could be identified 
within the gland-like structures. The capacity to form these structures decreased in cultures of 
higher passage number. The maximal life span of epithelial cultures was eight passages.
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Figure 2. A,B Morphology of prostate epithelial cell culture. Gland-like buds and extensions 
are formed on top of the monolayer after confluence.
Keratin expression in vitro
Based on their keratin expression, three epithelial cell types were distinguished growing in the 
monolayer. Two cell types were strongly positive for K5 and 14. Most of these cells weakly 
co-expressed K18 (K5++/14++/18+) associated with a basal cell phenotype, and few cells 
showed intense expression of K18 (K5+/14+/18++). These cells (K5+/14+/18++) either had an 
angular shape or showed several cytoplasmic extensions that seemed to contact neighbouring 
cells suggestive for neuro-endocrine differentiation. This particular cell type was growing 
either within or on top of the monolayer. A third cell type expressed K5 and 18, but not K14 
(K5+/18+). Subtle variations were observed in the quantity of the respective keratins, 
indicating up- and down-regulation of these proteins. Figure 3 (Appendix).
At the beginning of gland-like budding, small cell groups emerged above the 
monolayer and were positive for both K5 and 18, or K18 alone. The gland-like buds and 
extensions had a complex cell composition in which outer and inner cell compartments were 
distinguished as analysed by CLSM. The outer layer consisted predominantly of flat cells that 
expressed K5, 14 and 18 (K5++/14++/18+) to the same extent as the cells growing in 
monolayer. Cells in the central part of the gland-like structures were usually positive for K18 
alone, or showed co-expression of K5 and 18 (K5+/18+). Figure 4 (Appendix).
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The expression of activated caspase-3 was analysed to exclude the possibility that 
multicellular buds and extensions were merely aggregations of apoptotic cells that had 
released from the monolayer. Single cells found on top of the monolayer and few cells within 
the multicellular structures expressed activated caspase-3 indicative for apoptosis. However, 
most cells within the gland-like structures did not reveal signs of apoptosis.
Secretion of PSA, chromogranin A, and serotonin occurs during differentiation in the 
prostate. Within the monolayer and gland-like structures, dispersed cells showed exocrine 
differentiation identified by PSA expression. There was no expression of chromogranin A or 
serotonin, particularly not in cells with cytoplasmic extensions. This contrasts with the 
morphology of these cells, which was suggestive of neuro-endocrine differentiation.
Discussion
Keratins are a subclass of cytoskeletal proteins that serve as specific differentiation markers 
for normal epithelium as well as for cancer cells (8). Simultaneous analysis of K5, 14, and 18 
expression demonstrates a gradual shift of these proteins during epithelial differentiation in 
the prostate and is a useful tool for discriminating epithelial subpopulations. Basal cells within 
the normal prostate epithelium express either K5/14/18 or K5/18. Although K18 is generally 
seen as a luminal cell marker, several reports describe its basal expression on the mRNA and 
protein level (12,13). This inconsistency might be explained by the low expression intensity 
of K18 in the basal cell layer, as shown in this study. Whereas the majority of luminal cells 
show expression of K18 alone, co-localization of K5/18 is regularly encountered. The 
heterogeneous expression of keratins, as described in this study, was indicated previously in 
an indirect way (3,14). Direct triple-staining advantageously potentiates epithelial 
characterization in culture and the analysis of additional markers in intermediate cell stages. 
The keratin profiles described in this study suggest a hierarchic relationship within the human 
prostate epithelium in which a putative stem cell population (K5++/14++/18+) gives rise 
successively to intermediate cells (K5++/18+ and K5+/18++) and terminally differentiated cells 
(K18++).
A cell culture model was developed to study the kinetics of epithelial differentiation. 
Two growth phases can be distinguished in epithelial cell culture. The first expansion phase is 
characterized by growth of cells in the monolayer that express K5 and K14 with minor 
expression of K18, indicating a basal cell phenotype. The predominance of basal cells in 
primary culture corresponds with the observations of others (4,24,25). The triple-staining
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technique enabled the detection of two distinct cell types, with an intermediate keratin 
expression pattern in monolayer. The first cell type expressed high levels of K5, K14, and 
K18. The second cell type expressed K5 and K18, but did not express K14. A second phase of 
differentiation manifested after confluence was characterized by the emergence of gland-like 
buds and extensions. Confocal scanning microscopy demonstrates that these structures are 
composed of an outer “basal” cell layer (K5++/14++/18+) and a central compartment containing 
intermediate (K5+/18+) and “luminal” cells (K18). The sequence of growth phases and the 
identification of gradual keratin shifts in intermediate cells strongly indicate that basal cells 
are progenitors of the luminal cells in the human prostate epithelium. Definite evidence for 
the stem cell hypothesis should, however, be obtained by tracking a pure epithelial cell 
population and demonstrating its capability to differentiate into all other epithelial cell types 
in the prostate, combined with ontogenic studies of prostate epithelial development (7,26).
The hierarchic relationship of prostate epithelium was further indicated by the focal 
expression of PSA in multicellular buds as a marker for exocrine differentiation. We assume 
that PSA expression in the monolayer is localized in intermediate cells, because Bonkhoff et 
al. found co-localization of basal cell markers and PSA expression in the normal prostate 
(15). Apoptosis occasionally occurred in gland-like structures as demonstrated by caspase-3 
activity. Interestingly, activated caspase-3 is usually located in the luminal cell compartment 
and might indicate the end-stage of differentiation in cell culture (22). To our surprise, we 
were not able to prove neuro-endocrine differentiation in cell culture. Although cellular 
neurite-like extensions contacting neighbouring cells morphologically suggested neuro­
endocrine differentiation, these cells did not express chromogranin A or serotonin. It is 
possible that other neuro-endocrine granula are produced by these cells or that extra stimuli 
are necessary for the production of neuro-endocrine granula (27-29).
In our opinion a subgroup of basal cells that express K5++/14++/18+ corresponds to the 
stem cell population in the human prostate epithelium. The majority of the basal cells, 
however, represent early intermediate or TP/ amplifying cells (5,7,30). In these cells, 
expression of K14 is gradually decreased, leading to a well-defined intermediate phenotype 
characterized by expression of K5 and 18. In some luminal cells, up-regulation of K18 takes 
place during loss of K14, representing another intermediate phenotype (K5+/14+/18++). Loss 
of K5 seems to represent a late event in epithelial differentiation, resulting in cells strongly 
positive for K18. Despite the finding of epithelial cell stages with intermediate keratin 
expression, it is not possible to adequately mark early and late intermediate cell stages. 
Gradual shifts in keratin expression during differentiation imply that intermediate keratin
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profiles partially overlap with putative stem cells (K5++/14++/18+) and terminally 
differentiated, luminal cells (K18++), respectively. Several other proteins might be useful to 
mark stem, intermediate TP/ amplifying and terminally differentiated cells more adequately, 
because the expression pattern of multiple genes is changed during differentiation. P- 
cadherin, Glutathione S-Transferase PI, bcl-2, Prostate Stem Cell Antigen, phosphoprotein 
32, and Epidermal Growth Factor Receptor are all typically present in basal cells and are 
down-regulated during differentiation (19,31-37). Luminal cells, however, up-regulate 
Androgen Receptor, PSA, and p27/kip1 (15,38,39). Simultaneous analysis of these specific 
markers and keratin profiles gives insight into the cell biological characteristics of the distinct 
epithelial subpopulations.
In prostate carcinoma, several basal markers are expressed, in spite of the 
predominance of luminal cell characteristics in this malignancy (14,17,18,31,32,34). 
Interestingly, the expression of some basal cell markers is even more pronounced in 
androgen-independent prostate carcinoma (19,20). This led to the hypothesis that an 
intermediate cell population, the TP/ amplifying cell, forms the origin of malignant 
transformation in the prostate epithelium (14). The present model potentiates further analysis 
of the cell biological characteristics of intermediate cells and the molecular regulation of 
epithelial differentiation. Understanding these aspects will provide important information 
about the cellular origin of prostate carcinoma and its androgen-independent progression.
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Abstract
Prostate cancer is predominantly composed o f luminal and neuro-endocrine cells, while a minority o f cells has a 
basal phenotype. In order to distinguish between basal and intermediate cells, and to assess the effects of 
androgen-deprivation on prostate cancer we characterized 56 human prostate cancer metastases and 3 cancer 
cell lines using antibodies to K5, K14, K18 and the neuro-endocrine marker chromogranin A (ChA). The 
stainings were performed on paraffin tissue and visualized according to the avidin-biotin-peroxidase complex 
method. Protein expression was quantified as the number o f positive cells in 20 High Power Fields (400x). 
Keratin expression in the prostate cancer cell lines LNCaP, DU145 and PC3 was immunofluorescently analysed 
with triple-staining and confocal laser scanning microscopy. Prostate cancer metastases were consistently 
positive for K18 and negative for K14 irrespective o f hormonal therapy. K5 expression was displayed in 28.9% 
o f the tumours without treatment, in 75% after androgen-deprivation and 57.1% o f hormone-escaped prostate 
carcinomas. After androgen-deprivation, the number o f K5 expressing cells significantly increased. While 
androgen-dependent prostate cancer obtained a median o f 0 cells/ 20 HPF (range 0-50), regressed tumours 
displayed 22.5 (range 0-65) and hormone-escaped tumours 7.5 (0-361) positive cells/ 20 HPF. Expression o f 
ChA was observed in 47.4% o f the androgen-dependent tumours. The number o f neuro-endocrine cells was not 
significantly affected in regressed or hormone-escaped disease. The androgen-dependent cell line LNCaP 
stained for K18, while both androgen-independent lines DU145 and PC3 expressed K5 and 18. Expression o f K5 
in the absence o f K14 identifies the existence o f an intermediate cell population in prostate carcinoma. 
Accumulation o f intermediate cells in regressed and hormone-escaped prostate cancer indicates that these cells 
are androgen-independent for their survival.
Introduction
The human prostate epithelium is composed of luminal cells with secretory activity, basal 
cells, and dispersed neuro-endocrine cells. The entire epithelium putatively originates from a 
stem cell population that is situated in the basal cell layer (1-3). These stem cells have a long 
life span and a large proliferative capacity. After mitosis, they give rise to a duplicate stem 
cell and an amplifying cell that has limited cyclic activity and a short life span. During 
transient proliferation amplifying cells mature towards more committed exocrine or neuro­
endocrine cells. These cells finally become post-mitotic and undergo terminal differentiation.
Carcinoma of the prostate gland is the second most frequent malignancy in western 
men (4). At the time of diagnosis prostate cancer is clinically considered as an androgen- 
dependent tumour and androgen-deprivation is standard treatment for metastasized disease. 
Although permanent androgen-deprivation initially leads to tumour regression, most prostate 
carcinomas eventually show signs of androgen-independent progression for which no 
therapeutic options are currently available. Little is known about the cell biological
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mechanisms that are responsible for this androgen-independent progression of prostate 
carcinoma, which hampers the development of new treatment modalities for this malignancy.
The analysis of prostate carcinogenesis and androgen-independent disease progression 
requires understanding of the epithelial cell populations involved in this malignancy. 
Expression of keratins (K) has gained validity for the identification of subpopulations in the 
normal and malignant prostate epithelium. In normal prostate, basal cells specifically express 
the high-molecular-weight keratins 5 and 14, while a subpopulation shows expression of K5 
without K14 (5). Although weak expression of K8 and 18 is encountered in basal cells, strong 
expression of K8 and 18 in the absence of K14 is characteristic for luminal epithelium of the 
prostate (6,7). A subpopulation of luminal cells, however, demonstrates co-expression of K5, 
8 and 18 (5,8). Furthermore, exocrine and neuro-endocrine cells can be distinguished in the 
normal prostate epithelium, based on their secretory products. The secretion of Prostate 
Specific Antigen (PSA) characterizes exocrine differentiation in prostate luminal epithelium, 
while neuro-endocrine cells are generally identified by their expression of neuropeptides, such 
as chromogranin A (ChA).
Prostate carcinoma is composed of phenotypically exocrine, luminal (K18, PSA) and 
dispersed neuro-endocrine (ChA) cells. It was long believed that prostate carcinoma lacked 
basal cells, as many investigators had shown the absence of “basal” cell keratins in prostate 
adenocarcinoma (9-11). Reactivity of the antibody 34PE12 (anti-K1, 5, 10, 14) is therefore 
commonly applied for the distinction of atypical benign lesions suspicious for malignancy and 
adenocarcinoma (11,12). During the last decade, a few studies unexpectedly demonstrated the 
expression of “basal” cell keratins in prostate carcinoma. Co-localization of K5 and K18 was 
encountered in a subgroup of primary prostate tumours (8,13). The analysis of keratin 
expression in primary prostate carcinoma can be very difficult, as several benign lesions or 
pre-existent prostate glands might be mistaken for adenocarcinoma, especially after androgen­
deprivation. Reactivity of the antibody 34PE12 was, however, additionally shown in prostate 
cancer metastases that were entirely composed of malignant cells, thereby avoiding confusion 
with lesions mimicking adenocarcinoma (14,15). These findings suggest that human prostate 
cancer has a more complex cellular composition.
In this study, we analysed the expression of K5, 14, 18 and chromogranin A in 
prostate cancer metastases to elucidate further the different epithelial phenotypes involved in 
this malignancy. Additionally, we studied changes in the cellular composition of regressed 
and hormone-escaped prostate cancer. Finally, the phenotype of three human prostate cancer 
cell lines with different states of androgen-dependency was determined.
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Materials and Methods
Tissue specimens
A total of 56 tissue samples were obtained from 56 prostate cancer patients who had 
successively been operated for tumour metastasis. The metastatic lesions were localized in 
lymph nodes (N=47), bone (N=8) and skin (N=1). Eighteen patients underwent androgen­
deprivation therapy at the time of surgical removal of the metastasis. In four of these cases, 
the history revealed tumour regression in response to therapy, defined by reduction of serum 
PSA levels or a clinical decrease of tumour load. Fourteen patients had signs of hormone- 
escaped, androgen-independent disease progression at time of surgery, defined by an increase 
in serum PSA levels or an increase of tumour mass during androgen-deprivation.
Cell lines
The human prostate cancer cell lines LNCaP, DU145 and PC3 were purchased from the 
American Type Culture Collection (ATCC). LNCaP (passage 51), DU145 (passage 110) and 
PC3 (passage 54) were maintained in a humidified incubator (95%O2; 5% CO2) and covered 
with RPMI 1640 medium supplemented with 10% foetal calf serum and 2 mM glutamine 
(GibcoBRL, Paisley, UK). For immunohistochemical characterization, cell lines were grown 
on glass slides until confluence.
Antibodies
The antibodies DC 10 (K18) and anti-ChA were obtained from DAKO, Glostrup, Denmark; 
LL002 (K14) was derived from BioGenex, San Ramon, CA, USA. RGE53 (K18), RCK103 
(K5), and RCK107 (K14) were a kind gift from Dr. F. Ramaekers, University of Maastricht, 
The Netherlands (8). The reaction patterns of the two antibodies to K18 (DC10, RGE53) were 
identical, as were those of the antibodies to K14 (LL002, RCK107).
Indirect immunohistochemistry
Immunohistochemical studies were performed on 4 p,m sections that had been cut from 
fomaldehyde-fixed, paraffin embedded tissue. Slides were dewaxed and rehydrated using 
xylene and ethanol, respectively. After immersion in 10 mmol/l citrate buffer (pH 6.0), the 
slides were subjected to microwave irradiation (600 W) for 2 x 5 min, except for anti-ChA. 
Endogenous peroxidase activity was quenched for 30 min with 40% methanol containing 
0.6% H2O2. All antibodies were diluted in phosphate buffered saline (PBS) containing 5%
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bovine serum albumin (BSA) and incubations were performed in the dark at room 
temperature (r.t.) unless stated otherwise. After pre-incubation with 10% normal swine serum 
for 10 min, the slides were incubated overnight at 4°C with primary monoclonal antibodies 
directed towards K5 (RCK103; 1:5), K14 (LL002; 1:100), K18 (DC10; 1:50) or a rabbit 
polyclonal antibody towards ChA (1:1000). After washing in PBS the slides were incubated 
with biotinylated sheep anti-mouse (1:200) or donkey anti-rabbit (1:200) antibody for 30 min, 
followed by conjugation with 1:100 diluted avidin-biotin-peroxidase complex (Vectastain, 
Vector Laboratories, Burlingame, CA, USA) for 30 min. Chromogenic development resulted 
from incubation of slides with 0.76% (w/v) 3,3’-diaminobenzidine tetrahydrochlorid 
containing 0.00075% (v/v) H2O2 for 10 min and was enhanced after exposure to a dilution of 
0.5% CuS04/0.9% NaCl for 5 min. All slides were counterstained with hematoxylin. 
Immunohistochemical protein expression was quantified by counting the number of positive 
cells in 20 consecutive high power fields 400x (HPF) in the tumour.
Direct antibody labelling
Monoclonal antibodies towards K18 (RGE53) and K5 (RCK103) were directly labelled with 
fluorescent dyes using Alexa™ P488 and Alexa™ P546 protein labelling kits (Molecular 
Probes, Eugene, OR, USA) according to the manufacturer’s guide. Briefly, 1.0 mg of purified 
antibody was dissolved in 0.5 ml PBS and alkalinized using 50 ^l of sodium bicarbonate (1 
M) to optimize labelling conditions. The antibody solutions reacted for 1 hour with 
succinimidyl esters of Alexa™ P488 (RGE53) and Alexa™ P546 (RCK103) carboxylic acid. 
Reactions were blocked by addition of 17 ^l and 15 ^l hydroxylamine, respectively. After 
incubation for 30 and 15 min, the labelled antibody was separated from the unincorporated 
dye using a resin column. The antibody concentration and labelling efficiencies were analysed 
by spectrophotometry. The labelling efficiencies of RGE53 and RCK103 were 6.5 (optimal 
labelling, 4-9) and 3.6 (optimal labelling, 2-7), respectively. The total labelling procedure was 
performed in the dark at room temperature.
Triple-staining procedure
Cell lines grown on glass slides were fixed in acetone for 10 min at -20°C and air-dried for 2 
hours. The slides were incubated with an undiluted monoclonal antibody towards K14 
(RCK107) for 60 min. After washing in PBS, the slides were incubated with biotinylated 
sheep anti-mouse Ig (1:100) for 30 min and conjugated with streptavidin-Cy5 (1:20) for 30
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min. Free binding sites were blocked with 10% normal mouse serum during 30 min. After 
extensive washing, the slides were incubated with directly labelled RGE53 (20 ^g/ml) and 
RCK103 (5 ^g/ml) for 1 hour. All dilutions were made in PBS/1% BSA and incubations were 
performed in the dark at r.t. The slides were mounted with fluorescent mounting medium 
(DAKO) and analysed using confocal laser scanning microscopy (CLSM; The Confocal 
System LEICA TCS NT, Leica, Wetzlar, Germany).
Statistics
The prevalence of K5 and ChA expression in tumours was analysed using the Pearson %2 test. 
Differences in the distribution of K5 and ChA as measured by counting the number of 
positive cells in 20 HPF, were evaluated using the Mann-Whitney U-test. A probability (p) 
value of less than 5% was considered significant. The analyses were performed with the 
Statistical Software for Social Sciences (SPSS) software, version 9.0.
Results
Characterization o f prostate carcinoma metastases
Immunohistochemical examination of prostate carcinoma metastases revealed diffuse and 
strong expression of K18 in all cases. Figure 1. Discordance existed in the expression of the 
“basal” cell keratins 5 and 14. While 11 out of 38 (28.9%) tumours without androgen­
deprivation demonstrated expression of K5, none of the metastases expressed K14. 
Expression of K5 occurred in small cell clusters as well as in single cells. K5-positive cells 
were not only present in established metastases of prostate carcinoma, but also within tumour 
cell emboli localized in vessels close to lymph nodes. While the majority of cells constituting 
these emboli expressed only K18, K5 was predominantly localized at the periphery of these 
tumour masses. Figure 2. Expression of ChA was identified in 18 out of 38 (47.4%) 
metastases and was localized in single cells or cell clusters. Neuro-endocrine differentiation 
was not observed in lymphatic tumour emboli.
To investigate whether androgen-withdrawal affects the cellular composition of 
prostate carcinoma metastases, we compared androgen-dependent, regressed and hormone- 
escaped prostate tumours. Androgen-deprivation did not affect the expression of K18. 
Likewise, in androgen-dependent tumours, expression of K14 was not found in prostate 
carcinoma after androgen-deprivation. Tables 1 and 2 illustrate the expression profiles of K5
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and ChA during androgen-deprivation and in hormone-escaped prostate cancer. K5 was 
identified in three out of four (75%) tumours showing regression upon androgen-deprivation. 
The number of K5-positive cells increased significantly to 22.5 cells/ 20 HPF (median; range 
0-65/ 20 HPF), compared with 0 cells/ 20 HPF in controls (median; range 0-50/ 20 HPF) 
(p<0.03; Mann-Whitney). K5-expression was observed in 8 out of 14 (57.1%) hormone- 
escaped prostate carcinomas, compared with 28.9% in androgen-dependent tumours (p=0.02; 
X2 test). The median cell number of K5 expressing cells enhanced from 0 to 7.5 positive cells/ 
20 HPF (median; range 0-361/ 20 HPF) in hormone-escaped disease (p=0.02; Mann­
Whitney).
Figure 1. Expression of K5, K18 and chromogranin A in a prostate cancer lymph node 
metastasis. A All malignant cells show strong expression of K18. B,C K5 (B; arrow-heads) 
and chromogranin A (C) are both expressed in a subpopulation of malignant cells.
The prevalence of ChA expression did not change significantly in regressed and hormone- 
escaped prostate carcinoma. There was a weak trend to accumulation of neuro-endocrine cells 
in the four regressed tumours. After androgen-deprivation, 12 cells/ 20 HPF (median; range 0- 
137/ 20 HPF) were identified in regressed tumours, compared to 0 (0-346/ 20 HPF) in
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androgen-dependent prostate carcinoma. There was no significant change in the occurrence of 
neuro-endocrine differentiation in hormone-escaped prostate carcinoma.
Table 1. Prevalence of K5 and ChA expression in prostate carcinoma metastases: hormone-dependent prostate 
cancer (no treatment), tumours that showed regression upon androgen-deprivation (regressed), and hormone- 
escaped prostate carcinoma (escaped)
Location No treatment
Keratin 5 
Regressed Escaped No treatment
Chromogranin A 
Regressed Escaped
Lymph node 10/36 (27.8%) 3/4 (75%) 3/7 (42.9%) 18/36 (50%) 2/4 (50%) 5/7 (71.4%)
Bone 1/2 (50%) - 4/6 (66.7%) 0/2 (0%) - 2/6 (33.3%)
Skin - - 1/1 (100%) - - 0/1 (0%)
Total 11/38 (28.9%) 3/4 (75%) 8/14 (57.1%)* 18/38 (47.4%) 2/4 (50%) 7/14 (50%)
*p=0.02 (Pearson %2)
Table 2. Median and range of number K5 and ChA expressing tumour cells in prostate cancer metastasis as 
determined by counting positive cells in 20 consecutive High Power Fields.
Location No treatment
Keratin 5 
Regressed Escaped No treatment
Chromogranin A 
Regressed Escaped
Lymph node 0 (0-50) 22.5 (0-65) 0 (0-25) 0.5 (0-346) 12 (0-137) 3 (0-640)
Bone 0.5 (0-1) - 54 (0-361) 0 - 0 (0-23)
Skin - - 131 - - 0
Total 0 (0-50) 22.5 (0-65)* 7.5 (0-361)** 0 (0-346) 12 (0-137) 1 (0-640)
*p<0.03 (Mann-Whitney); **p=0.02 (Mann-Whitney)
Keratin expression in cell lines
In order to identify co-expression of keratins in single cells, we developed a technique for the 
simultaneous analysis of K5, 14, and 18 using confocal laser scanning microscopy (CLSM) 
(5). The different keratins are characterized by specific fluorescent signals that are compiled 
into coloured images. While a red colour in these images represents expression of K5, a blue 
colour is specific for K14 and green for K18. Co-expression of keratins is depicted as a hybrid 
colour. Co-localization of K5 (red) and K18 (green) for example gives a yellow hybrid colour.
The prostate cancer cell lines LNCaP, DU145 and PC3 revealed distinct keratin 
expression patterns. The androgen-dependent cell line LNCaP strongly expressed K18 
(green), but not K5 and 14. In contrast, the androgen-independent cell line PC3 
homogeneously co-expressed K5 and 18, while it lacked K14 (yellow hybrid colour). 
Interestingly, a heterogeneous expression pattern of K5 and 18 in the absence of K14 was 
observed in the androgen-independent cell line DU145. Whereas most cells co-expressed K5 
and 18 at the same level (yellow hybrid colour), a subpopulation of cells had low K5 levels.
44
Intermediate cells in prostate cancer
These cells are identified by a hybrid colour that is more green (K18) than yellow (K5/18). 
Figure 3 (Appendix).
Discussion
Prostate carcinoma is predominantly composed of cells with a luminal, exocrine phenotype 
(K18, PSA), whereas dispersed cells with neuro-endocrine differentiation (ChA) are regularly 
present (9-11,16). Many reports have described the absence of pre-existing basal cells in 
prostate carcinoma; reactivity of the 34PE12 antibody (anti-K 1, 5, 10, 14) has therefore been 
used as a hallmark for distinguishing between atypical benign lesions suspicious for 
malignancy and adenocarcinoma. During the last decade, however, a few groups found 
expression of high-molecular-weight keratins in prostate tumours. Reactivity of 34PE12 was 
reported in 4 to 54% of prostate carcinoma metastases (14,15). In primary prostate carcinoma, 
K5 but not K14 was encountered (8,13). The identification of high-molecular-weight keratins 
in primary prostate carcinomas should, in our opinion, be interpreted with caution, as several 
non-malignant histopathologic conditions might be mistaken for adenocarcinoma (11,12). 
Prostatic Intraepithelial Neoplasia (PIN), atypical adenomatous hyperplasia, and lobular 
hyperplasia, for instance, can mimic prostate carcinoma and they all reveal reactivity with 
34PE12. Furthermore, malignant lesions might entrap pre-existing glands and making the 
distinction between the two components might be difficult. We analysed the expression of 
keratins and ChA in human prostate carcinoma to characterize further the epithelial cell types 
that are involved in this malignancy. To prevent diagnostic misinterpretation, we studied 
prostate cancer metastases, because these are completely composed of malignant cells.
Based on the expression of keratins and ChA, we identified three epithelial cell types 
in human prostate carcinoma. Phenotypically luminal cells (K18) were the predominant cell 
population in prostate carcinoma (1). A distinct cell type was characterized by expression of 
ChA, indicating the presence of neuro-endocrine cells (2). A third cell population was 
identified by the expression of K5 in the absence of K14 (3). As prostate carcinoma is 
considered a monoclonal expansion of a transformed epithelial cell type, its heterogeneous 
cellular composition is intriguing and needs further investigation. Because distinct epithelial 
cells are simultaneously present in prostate carcinoma, one of these should be the progenitor 
of the other two cell populations. Several authors postulated such a hierarchic relationship in 
the non-malignant prostate epithelium, in which stem cells give rise to intermediate
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amplifying cells, which transiently proliferate and differentiate into committed exocrine or 
neuro-endocrine cells (1,2,8,17). The stem cell population is putatively characterized by the 
keratin expression pattern K5++/14++/18+ and is found in the basal cell layer. Amplifying cells 
are localized in the basal as well as the luminal cell layer and they have an intermediate 
keratin expression of K5++/18+ (basal) or K5+/18++ (luminal), while terminally differentiated 
cells express K18++ (3,5,8). Based on the hypothesized histogenesis of the normal epithelium, 
Verhagen et a1. postulated that malignant transformation in the prostate arose initially in the 
intermediate amplifying cell population (8). In their view, this neoplastic cell population at 
least partially retains the potency to differentiate into more committed cells and will finally 
undergo terminal differentiation in prostate carcinoma. Interestingly, De Marzo et al. found 
that intermediate cells do not express the cell-cycle dependent kinase inhibitor p27/kip1, 
meaning that they have proliferative capacity (18). On the contrary, expression of p27/kip1 in 
the majority of exocrine, luminal cells and the absence of the cell proliferation marker Ki-67 
in neuro-endocrine cells suggest that these cells do not reveal cyclical activity and are 
therefore less likely to undergo malignant transformation (19). Further analysis of the 
biological characteristics of the intermediate cell group and the dynamics of its differentiation 
should, however, provide further evidence for its role in prostate carcinogenesis.
Figure 2. A,B Expression of K5 in a tumour embolus of prostate carcinoma localized in a 
lymph vessel close to a lymph node. K5-expressing cells are predominantly found at the 
periphery of the tumour embolus (arrow-heads).
The postulation that intermediate amplifying cells are initially involved in prostate 
carcinogenesis raises the question of why their presence could not be demonstrated 
immunohistochemically in all tumours. There are two explanations for this ostensible 
inconsistency. Firstly, K5-expressing intermediate cells constitute a small population of 
prostate carcinoma and might be missed due to sampling errors. Furthermore, intermediate
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amplifying cells represent a dynamic cell population, in which protein expression profiles are 
gradually modulated from a basal cell phenotype towards a committed, luminal phenotype. 
During this process, K18 is up-regulated while the expression of K5 diminishes before the 
cells achieve a steady-state level of terminal differentiation. Therefore, “early” intermediate 
cells are likely to express K5, while more committed, “late” intermediate cell do not any 
more. Prostate carcinoma without expression of K5 could consequently be derived from 
“late” intermediate cells.
Based on the presented data, however, it cannot be excluded that the presence of basal 
cell keratin 5 in prostate carcinoma represents an example of aberrant protein expression, or is 
a feature of dedifferentiation in prostate cancer. Aberrant expression of intermediate filaments 
is a common observation in human malignancies. While vimentin is not present in non- 
malignant tubular epithelium of the kidney, co-localization of vimentin and keratin can be 
recognized in renal carcinomas (20). Furthermore, keratins might be expressed in non­
epithelial malignancies such as sarcomas and melanomas, whereas they are not in normal soft 
tissue and melanocytes (21). Irrespective on the molecular pathway leading to cells 
phenotypically resembling intermediate cells, analysis of this specific cell population might 
contribute to a better understanding of androgen-independent prostate cancer progression.
The increase of intermediate cells after androgen-deprivation indicates that these cells 
are not dependent on androgens for their survival. Intermediate amplifying cells therefore 
remain unaffected during androgen-deprivation in contrast to terminally differentiated cells 
that undergo apoptosis. Changes in the expression patterns of other proteins have also 
indicated a shift from a luminal towards more intermediate/basal phenotype in androgen- 
resistant prostate cancer. Immunohistochemical expression of PSA in malignant cells declines 
during androgen-deprivation (22). Furthermore, Epidermal Growth Factor Receptor (EGFR) 
and bcl-2, normally localized in the basal cell layer, accumulate during androgen-deprivation 
(13,23). It would be interesting if these proteins were also expressed in intermediate cells, as 
this would provide important information about the biological mechanisms leading to 
androgen-independent survival of intermediate cells. Expansion and differentiation of the 
intermediate amplifying cell population during androgen-deprivation might subsequently lead 
to androgen-independent progression of prostate carcinoma. Interestingly, the association of 
intermediate cells with androgen-independent prostate carcinoma was also reflected in cell 
lines. While the androgen-dependent cell line LNCaP expressed only K18, the androgen­
independent cell lines PC3 and DU145 were both characterized by expression of K5 and K18.
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Therefore, DU145 and PCS could be of use for the study of intermediate cell differentiation in 
prostate carcinoma.
We were not able to find a significant association of neuro-endocrine differentiation 
and androgen-resistant prostate carcinoma, in contrast to earlier reports of an increase of 
neuro-endocrine differentiation in primary prostate carcinoma during neoadjuvant androgen­
deprivation (24-26). Although there was a trend towards accumulation of neuro-endocrine 
cells in regressive tumours, the numbers were too small for a significant correlation. Recently, 
it was demonstrated that a number of physiological and pharmacological agents, such as db- 
cAMP, Epi, Fsk, interleukin (IL)-1 and -6, induced neuro-endocrine differentiation in 
prostate cancer cell lines (27-29). This suggests that induction of neuro-endocrine 
differentiation is regulated by paracrine and endocrine factors. We therefore suggest that 
micro-environmental conditions affect neuro-endocrine differentiation and might be 
responsible for the different results in primary and metastatic prostate carcinoma.
Prostate adenocarcinoma is histolocally characterized by the absence of a basal cell 
layer; the immunohistochemical detection of basal cells is therefore a valuable diagnostic tool 
for distinguishing between benign lesions suspicious for malignancy and prostate cancer. 
Antibodies directed to “basal” keratins, such as S4ßE12 (anti-K1, 5, 10, 14) are generally 
applied for the detection of basal cells in suspicious lesions. As shown in this and other 
studies, it is important to realize that these antibodies might also be reactive in a subset of 
prostate carcinoma cells, due to their expression of K5. This raises the question of whether 
demonstration of “basal” keratins can reliably distinguish between benign and malignant 
lesions in the prostate. We strongly believe that the diagnosis of adenocarcinoma of the 
prostate should be primarily based on specific architectural and cytological changes of 
prostate tissue; immunohistochemical evaluation of basal cells should have an affirmative 
rather than a decisive role in the diagnosis. It is well known that the basal cell layer is often 
incomplete in benign prostate lesions, so that absence of basal cells does not necessarily 
justify the diagnosis of prostate carcinoma. On the other hand, expression of the “basal” cell 
keratin 5 occurs in non-malignant luminal epithelium as well as in prostate carcinoma. This 
indicates that reactivity of S4ßE12 within cubical or columnar cells does not distinguish 
benign lesions mimicking prostate carcinoma from actual malignancy. In our opinion, the 
immunohistochemical analysis of keratins is therefore only valuable for the demonstration of 
morphologically basal cells in suspicious benign lesions, thus excluding the diagnosis of 
prostate carcinoma.
48
Intermediate cells in prostate cancer
References
1. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989; 
2: 33-50
2. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal 
prostatic growth: a stem cell model. Prostate 1996; 28: 98-106
3. Verhagen APM, Aalders TW, Ramaekers FCS, Debruyne FMJ, Schalken JA. Differential expression of 
keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and 
regeneration. Prostate 1988; 13: 25-38
4. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J  Clin 2000; 50: 7-33
5. Van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Demonstration of 
intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining 
confocal scanning microscopy. Lab Invest2000, 80: 1251-1258
6. Yang Y, Hao J, Liu X, Dalkin B, Nagle RB. Differential expression of cytokeratin mRNA and protein in 
normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma. Am J  Pathol 1997; 150: 693­
704
7. Nagle RB, Brawer MK, Kittelson J, Clark V. Phenotypic relationships of prostatic intraepithelial 
neoplasia to invasive prostatic carcinoma. Am J  Pathol 1991; 138: 119-128
8. Verhagen APM, Ramaekers FCS, Aalders TW, Schaafsma HE, Debruyne FMJ, Schalken JA. 
Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 1992; 52: 
6182-6187
9. Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A. Cytokeratin characterization 
of human prostatic carcinoma and its derived cell lines. Cancer Res 1987; 47: 281-286
10. Okada H, Tsubura A, Okamura A, Senzaki H, Naka Y, Komatz Y, Morii S. Keratin profiles in 
normal/hyperplastic prostates and prostate carcinoma. Virchows Arch A Pathol Anat Histopathol 1992; 
421: 157-161
11. O'Malley FP, Grignon DJ, Shum DT. Usefulness of immunoperoxidase staining with high-molecular- 
weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows 
Arch A Pathol Anat Histopathol 1990; 417: 191-196
12. Wojno KJ, Epstein JI. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the 
diagnosis of prostate cancer. A review of 228 cases. Am JSurg  Pathol 1995; 19: 251-260
13. Gil-Diez de Medina S, Salomon L, Colombel M, Abbou CC, Bellot J, Thiery JP, Radvanyi F, Van der 
Kwast TH, Chopin DK. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor 
expression during progression of prostate cancer. Hum Pathol 1998; 29: 1005-1012
14. Googe PB, McGinley KM, Fitzgibbon JF. Anticytokeratin antibody 34ßE12 staining in prostate 
carcinoma. Am J  Clin Pathol 1997; 107: 219-223
15. Yang XJ, Lecksell K, Gaudin P, Epstein JI. Rare expression of high-molecular-weight cytokeratin in 
adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate 
cancer. Am J  Surg Pathol 1999; 23: 147-152
16. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999; 39: 135-148
49
Chapter IV
17. Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic, and 
neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 
1994; 25: 42-46
18. De Marzo AM, Meeker AK, Epstein JI, Coffey DS. Prostate stem cell compartments: expression of the 
cell cycle inhibitor p27/kip1 in normal, hyperplastic, and neoplastic cells. Am J  Pathol 1998; 153: 911­
919
19. Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic 
adenocarcinoma are postmitotic cells. Hum Pathol 1995; 26: 167-170
20. Waldherr R, Schwechheimer K. Co-expression of cytokeratin and vimentin intermediate-sized filaments 
in renal cell carcinomas. Comparative study of the intermediate-sized filament distribution in renal cell 
carcinomas and normal human kidney. Virch Arch A Pathol Anat Histopathol 1985; 408: 15-27
21. Banks ER, Jansen JF, Oberle E, Davey DD. Cytokeratin positivity in fine-needle aspirates of melanomas 
and sarcomas. Diagn Cytopathol 1995; 12: 230-233
22. Ogreid P, Berner A, Dahl O, Rettedal E, Fossa SD. Tissue prostate-specific antigen and androgen receptor 
immunoreactivity in prostate cancer biopsies before, during and after neo-adjuvant androgen deprivation 
followed by radiotherapy. Eur Urol 1999; 36: 116-122
23. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. 
Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen­
independent prostate cancer. Cancer Res 1992; 52: 6940-6944
24. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during 
hormonal treatment. Urology 1998; 51: 585-589
25. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA. Regressive changes and 
neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 2000; 
42: 274-279
26. Abrahamsson PA. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate Suppl 
1996; 6: 3-8
27. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate 
tumour cells is reversible: implications for prostate cancer progression. Cancer Res 1999; 59: 3821-3830
28. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen 
P, Niklinski WT, Myers CE, Trepel JB. Terminal neuroendocrine differentiation of human prostate 
carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S  A 1994; 91: 
5330-5334
29. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer 
cells. Prostate 2000; 42: 186-195
50
Intermediate Cells in Normal and Malignant Prostate Epithelium 
Express the Proto-oncogen c-met
Geert J.L.H. van Leenders, Bianca van Balken, Tilly W. Aalders, 
Christina A. Hulsbergen-van de Kaa, Dirk J. Ruiter, Jack A. Schalken
V.
Prostate 2002; 51: 98-107
51
Chapter V
Abstract
Intermediate cells have been proposed as transiently proliferating, amplifying cells in the normal prostate 
epithelium and targets for prostate carcinogenesis. The expression o f the Hepatocyte Growth Factor (HGF) 
receptor c-met that has been associated with morphogenesis as well as malignant transformation, was studied in 
intermediate cells. Receptor localization was analysed using triple-staining for c-met, K5, K14 and K18. The 
percentage o f strongly c-met positive cells was determined in 15 prostate cancer patients undergoing androgen­
deprivation and 14 patients without neo-adjuvant treatment. Effects o f HGF were investigated on prostate 
cancer cell line DU 145. c-met expression in non-malignant epithelium was strong in intermediate, absent in 
differentiated and heterogeneous in basal cells. In prostate cancer, intermediate cells displayed high c-met levels 
coupled with mild expression in differentiated cells. During androgen-deprivation 7.6% o f tumour cells revealed 
high c-met expression compared to 1.7% without treatment (p=0.02). Matrigel penetration o f DU 145 was 
8.2+1.7 mm2 after HGF stimulation compared to 3.6±2.4 mm2 in controls (p<0.02). In conclusion, intermediate 
cells in normal and malignant prostate epithelium express high c-met levels indicating they are prone to stromal 
invasion in prostate carcinoma.
Introduction
Stromal-epithelial cell interactions are important for normal development and adequate 
function of the human prostate. During organogenesis, prostate tissue originates following the 
penetration and branching of the urogenital sinus epithelium into its adjacent mesenchym. In 
the adult, prostate stroma is necessary for normal epithelial differentiation (1). In addition to 
matrix deposition allowing the formation of three-dimensional epithelial glands, stromal- 
epithelial interactions are mediated by reciprocally secreted proteins.
Within the non-malignant prostate epithelium, basal and luminal cells can be 
discriminated by specific protein expression patterns. Luminal cells are characterized by 
intense expression of the Androgen Receptor (AR) and Prostate Specific Antigen (PSA), 
while basal cells express Epidermal Growth Factor Receptor (EGFR) and the proto-oncogen 
bcl-2 (2,3). Analysis of the keratin (K) expression profile demonstrates the existence of at 
least four different cell populations within the human prostate epithelium. Basal cells 
generally display high expression of K5 combined with low levels of K18, while K14 is only 
identified in subsets of basal cells (K5++/14++/18+ and K5++/18+). Strong expression of K8 and 
18 (K18++) is characteristic for luminal prostate epithelium. Co-localization of K5 in a group 
of luminal cells further reveals existence of an epithelial subpopulation characterized by an 
intermediate, basal-luminal phenotype (K5+/18++) (4-7).
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Two alternative stem cell models have been proposed for the development of the prostate 
epithelium. The first stem cell concept is based on epithelial dynamics observed upon 
deprivation and re-administration of androgens. In rodents, androgen-withdrawal leads to 
massive loss of luminal epithelium, while the basal cell layer largely remains unaffected. 
Upon restoration of circulating androgen-levels, particularly, luminal cells respond with 
proliferative activity, suggesting both cell layers are derived from separate stem cells (8-10). 
In vitro studies of the human prostate epithelium, however, indicate that basal cells 
(K5++/14++/18+) are progenitors of intermediate (K5/18) and luminal cells (K18++) (7,11,12). 
These results support the hierarchic stem cell model of Isaacs and Coffey postulating that the 
entire prostate epithelium is derived from a single stem cell population (13). According to this 
concept, basal cells characterized by K5++/14++/18+-expression represent stem cells that upon 
mitosis give rise to one stem cell copy (self renewal) and one intermediate (progenitor) cell. 
Intermediate cells subsequently amplify the development of the epithelium by transient 
proliferation and eventually differentiate into either exocrine or neuro-endocrine cells. During 
expansion, intermediate cells asynchronously switch their expression of K5, K14 and K18, 
successively leading to K5++/18+-, K5+/18++- and K18++-positive cells, while they translocate 
from the basal towards the luminal compartment.
Prostate cancer is a heterogeneous malignancy that is composed of cells exhibiting at 
least three different phenotypes. Luminal exocrine cells predominate in prostate cancer and 
can be recognized by expression of K18++, high levels of AR and PSA. A minority of 
malignant cells reveal neuro-endocrine differentiation characterized by secretion of neuro­
peptides as chromogranin A. Furthermore, expression of K5 in scattered tumour cells 
identifies the existence of cells with an apparent intermediate cell phenotype (K5+/18++) in 
prostate cancer (5). Androgen-deprivation and androgen-independent tumour progression are 
associated with an increase of both intermediate and neuro-endocrine cells indicating that 
these cell types are androgen-independent for their survival (14,15). In agreement with the 
hierarchic stem cell model, intermediate cells have been proposed as primary targets of 
malignant transformation in prostate cancer and precursors of androgen-independent tumour 
progression (5,13). Identification of their cell biological characteristics seems crucial for 
further understanding of the role of intermediate cells in prostate carcinogenesis.
Androgen-independent prostate cancer progression has been associated with over­
expression and activation of peptide growth factor receptors. EGFR mRNA is expressed at 
high levels in the androgen-independent cell lines DU145 and PC3, but at low levels in the 
androgen-dependent LNCaP (16). Transfection of HER-2/neu cDNA in LNCaP induced its
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transition from an androgen-dependent towards an androgen-independent state (17). Ligands 
of growth factor receptors are normally secreted by the prostate stroma, while their receptors 
are physiologically encountered in subpopulations of the non-malignant prostate epithelium. 
We hypothesize that peptide growth factor receptors are preferentially localized in 
intermediate cells as the presence of both peptide growth factor receptors and intermediate 
cells is associated with androgen-independent prostate carcinoma.
Hepatocyte Growth Factor/ Scatter factor (HGF) is a stroma-derived protein that binds 
to the high affinity tyrosine kinase receptor c-met localized within epithelial cells (18-20). 
HGF activates a number of biological functions in vitro, including cell motility, cell 
scattering, and cell invasion (21). In vivo, the HGF/c-met complex is involved in 
embryogenesis, morphogenesis, and angiogenesis (22,23). Furthermore, evidence is being 
accumulated for a role of HGF/c-met in tumour biology. Co-transfection of human HGF and 
c-met cDNA into NIH3T3 cells resulted in transformation and metastasis in mice (24,25). 
Additionally, over-expression of HGF/c-met has been reported in human epithelial 
malignancies derived from the colon, pancreas, lung and kidney (26-30). In prostate 
carcinoma over-expression of the receptor c-met has been found in 44 to 83% of the tumours
(20,27).
In this study, we show that c-met is localized in a subset of epithelial cells that appear 
intermediate in phenotype between basal and secretory cells in normal and malignant prostate 
epithelium. Stimulation of the prostate cancer cell line DU145 with HGF results in scattering 
and increased invasive capacity, suggesting that intermediate cells in prostate carcinoma are 
prone to stromal invasion.
Materials and Methods
Tissue collection and cell lines
Tissue samples were obtained from patients undergoing radical prostatectomy for prostate 
carcinoma. All patients gave informed consent for use of the specimens for research purposes. 
Immediately after surgery, a 4-mm transverse section of the prostate was snap-frozen in N2 
and stored at -80°C. The prostatectomy specimen was fixed in 10% neutral buffered 
formaldehyde and embedded in paraffin for histopathological evaluation.
Human prostate cancer cell lines LNCaP, DU145 and PC3 were purchased from 
American Type Culture Collection (ATCC; Rockville, MD, USA). LNCaP (passage 60),
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DU145 (passage 93-97) and PC3 (passage 58) were maintained in a humidified incubator 
(95%O2; 5% CO2) and covered with RPMI 1640 medium supplemented with 10% foetal calf 
serum and 2 mM glutamine (GibcoBRL, Paisley, UK).
Indirect immunohistochemistry
Immunohistochemical expression of c-met was studied in a total of 29 patients, of whom 15 
were undergoing neoadjuvant androgen-deprivation therapy at time of surgery for three to six 
months. Four p,m sections of paraffin embedded tissue were dewaxed and rehydrated using 
xylene and ethanol, respectively. After immersion in 10 mmol/l citrate buffer (pH 6.0) the 
slides were subjected to microwave irradiation (600 W) for 4 min. Endogenous peroxidase 
activity was quenched for 30 min with 40% methanol containing 0.6% H2O2. After pre­
incubation with 10% normal swine serum for 10 min, the slides were incubated with a 
dilution of 1:250 rabbit anti-human c-met antibody (C-28; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) for 1 hour at 37°C. The slides were washed in phosphate buffered saline 
(PBS) for 3 x 5 min followed by incubation with biotinylated donkey anti-rabbit (1:200) 
antibody for 30 min and conjugation with 1:100 avidin-biotin-peroxidase complex 
(Vectastain; Vector Laboratories, Burlingame, CA, USA) for 30 min. Chromogenic 
development resulted from incubation of slides with 0.76% (w/v) 3,3’-diaminobenzidine 
tetrahydrochloride containing 0.00075% (v/v) H2O2 for 10 min and was enhanced after 
exposure to a dilution of 0.5% CuSO4/0.9% NaCl for 5 min. All slides were counterstained 
with hematoxylin. All antibodies were diluted in PBS containing 5% bovine serum albumin 
(BSA) and incubations were performed in the dark at room temperature (r.t.) unless stated 
otherwise. The percentage of tumour cells that highly expressed c-met was determined by 
counting the number of strongly positive cells on a total of 500 tumour cells in representative 
areas of the carcinoma.
Direct antibody labelling
Monoclonal antibody towards K5 (RCK103; kind gift of Dr. F. Ramaekers, University of 
Maastricht, The Netherlands) was directly labelled with fluorescent dye using the Alexa™ 
P546 protein labelling kit (Molecular Probes, Eugene, OR, USA) according to the 
manufacturer’s guide. Briefly, 1.0 mg of purified antibody was dissolved in 0.5 ml PBS and 
alkalinized using 50 ^l sodium bicarbonate (1 M) to optimize labelling conditions. The 
antibody solutions reacted for 1 hour with the succinimidyl ester of Alexa™ P546 carboxylic 
acid. The reaction was blocked by addition of 15 ^l hydroxylamine. After incubation for 15
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min, the labelled antibody was separated from the unincorporated dye using a resin column. 
The antibody concentration and labelling efficiency were analysed by spectrophotometry. The 
labelling efficiency of RCK103 was 3.6 (optimal labelling, 2-7). The total labelling procedure 
was performed in the dark at r.t.
Triple-staining procedure
Cellular localization of c-met in prostate epithelium was analysed using immunofluorescent 
triple-staining combining K5/K18/c-met or K5/K14/c-met. Cryostat sections of 4 pm were 
fixed in acetone for 10 min at -20°C and air-dried overnight. The slides were incubated with a 
mixture of 1:250 rabbit anti-human c-met antibody and 1:50 mouse anti-human K18 antibody 
(DC10; DAKO, Glostrup, Denmark) or 1:100 K14 antibody (LL002; BioGenex, San Ramon, 
CA, USA) for 60 min, respectively. After washing in PBS, slides were incubated with a 
dilution of 1:100 biotinylated sheep anti-rabbit Ig and 1:200 goat anti-mouse Ig labelled with 
Alexa™ 488 (Molecular Probes) for 45 min followed by conjugation with 1:50 streptavidin- 
Cy5 for 45 min. Free Ig-binding sites were blocked with 10% normal mouse serum during 30 
min. After extensive washing, slides were incubated for 1 hour with a 5 pg/ml dilution of anti­
human K5 antibody (RCK103) directly conjugated with Alexa™ 546. All dilutions were made 
in PBS/1%BSA and incubations were performed in the dark at r.t. The slides were mounted 
with fluorescent mounting medium (DAKO) and analysed using confocal laser scanning 
microscopy (CLSM; The Confocal System LEICA TCS NT; Leica, Wetzlar, Germany).
Morphogenic effects o f  HGF
The cell lines LNCaP, DU145 and PC3 were seeded on 8-wells glass or Matrigel-coated 
slides (Nunc; GibcoBRL) at a density of 5 x 103 cells/well. After adherence of the cells 
overnight, the medium was replaced by D-MEM/F-12 without phenol-red (GibcoBRL) 
supplemented with HEPES (15 mM), transferrin (5 pg/ml), insulin (5 pg/ml), Na2SeO3 (5 
ng/ml) and BSA (1 mg/ml). Cell cultures were incubated with 25 ng/ml HGF (Sigma, Saint 
Louis, MO, USA) for 48 hours.
Matrigel invasion assay
The matrigel invasion assay used in this study was a modification from the one described 
originally (31). Briefly, inset chambers of a transwell system (pore size 8 pm; diameter 6.5 
mm; Corning, Acton, MA, USA) were coated with a dilution of 50 pg matrigel in 50 pi D-
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MEM/F-12 medium and incubated at 37°C for 1 hour to allow coagulation. The cell line 
DU145 was seeded into the inset chamber at a density of 50 x 103 in quatriplicate. After 
adherence overnight, the medium was changed into D-MEM/F-12 and 25 ng/ml HGF was 
added to the lower compartment of the transwell system. After incubation for 24 hours, cells 
were fixed for 60 min using 4% formaldehyde and washed overnight in PBS. Cells were 
stained with 0.002% (w/v) crystal violet for 2 hours and washed with tap water. Cells from 
the upper side of the inset were carefully removed using a cotton swab. After extensive 
washing, the membranes were dissected with a scalpel and placed on a glass slide with the 
upper side down. Coverslips were mounted with Permount. The number of cells that had 
penetrated matrigel was quantified using a grid composed of 25 squares measuring 40 pm2 
each (Leica).
Statistical analysis
Differences in the distribution of c-met expression after androgen-deprivation and in cases 
without treatment were evaluated using a non-parametric test (Mann-Whitney U). The 
invasive capacity of DU145 in the matrigel invasion assay was analysed using a Student t- 
test. A probability (p) value of less than 5% was considered significant.
Results
Immunohistochemistry
The receptor c-met was heterogeneously expressed in the non-malignant prostate epithelium. 
The majority of basal cells revealed strong staining for the c-met receptor, however, c-met 
expression was absent in some single cells and cell clusters. While c-met was not detectable in 
most of the columnar secretory luminal cells, high levels of the receptor were localized in 
focal cell clusters. Interestingly, expression of c-met was often detected in cubical and 
atrophic luminal cells, but only sporadically in high-columnar luminal cells. Figure 1. 
Staining of c-met was not observed in the prostate stroma.
Prostate carcinoma displayed a heterogeneous expression pattern for c-met. While a 
subgroup of malignant cells completely lacked the receptor, a majority of tumour cells 
expressed low levels of c-met. Strong c-met expression was encountered in 1.7% (median; 
range 0.6%-12.4%) of malignant cells. Figure 2. After neo-adjuvant androgen-deprivation, the 
number of cells that revealed high c-met levels was increased to 7.6% (median; range 0.6-
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62.8%). This enrichment was statistically significant (p=0.02; Mann-Whitney test) indicating 
that c-met is expressed in epithelial cells that are independent on androgens for their survival.
Figure 1. Expression of c-met in non-malignant prostate epithelium. Generally, c-met is 
localized in the basal cell layer but not in luminal cells (A). Expression of c-met is locally 
encountered in single cells (B; arrow-heads) as well as in cell clusters in the luminal 
compartment (C). Note absence of c-met is some basal cells (C; arrow-heads).
Immunofluorescent triple-staining
In order to subclassify the epithelial cell types expressing c-met, co-localization studies were 
performed using immunofluorescent triple-staining for K5/K14/c-met and K5/K18/c-met, 
respectively. There was no specific relation between c-met and the keratin profile in basal 
cells. Subsets of both K5++/18+- and K5++/14++/18+-positive basal cells revealed c-met 
expression but others did not express the receptor. In the luminal compartment, however, a 
strong relation was observed between c-met and epithelial cell phenotype. The receptor c-met 
was strongly and consistently expressed in cells with an intermediate phenotype (K5+/18++)
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even when K5 levels were low. In contrast, differentiated K18++-cells did not display any c- 
met expression. Figure 3 (Appendix).
Analysis of the keratin profile identified two cell types in prostate carcinoma. The vast 
majority of cells were K18++, but a minority of cells was K5+/18++ (intermediate). K14 was 
not expressed in prostate carcinoma (5). In accordance with c-met expression in the non- 
malignant epithelium, all malignant cells with an intermediate phenotype (K5+/18++) strongly 
expressed c-met, while expression was generally weak in K18++-positive cells.
Figure 2. Expression of c-met in prostate carcinoma. A mild generalized expression of c-met 
is demonstrated in the majority of malignant cells. Scattered tumour cells display high c-met 
levels (A,B; arrow-heads).
Effect o f  HGF on cell lines
The biological effects of HGF were investigated in prostate carcinoma cell lines LNCaP 
(androgen-sensitive), DU145 (androgen-independent) and PC3 (androgen-independent). Upon 
stimulation with HGF, DU145 cells grown on glass obtained a fibroblast-like morphology and 
scattered, while controls formed epitheloid cell clusters. On matrigel-coated slides, DU145 
cells grew in compact rounded cell clusters. After HGF stimulation, epithelial elongations 
appeared at the cell clusters’ edges and formed complex meshworks after a few days. HGF 
did not have any morphogenic effects on LNCaP and PC3. Figure 4. To determine whether 
HGF also affects the invasion of DU145, we performed a matrigel invasion assay. The area 
covered with DU145 cells that had penetrated Matrigel upon HGF stimulation was 8.2±1.7 
mm2 opposed to 3.6±2.4 mm2 in controls. This indicates that HGF significantly up-regulates 
the invasive capacity of DU145 (p<0.02; Student t-test).
59
Chapter V
Discussion
Intermediate cells in the prostate epithelium were first recognized by co-localization of basal 
and luminal cell markers. Verhagen et al. described the existence of cells with a ‘basal’ 
immunophenotype, that is expressing K5, in the luminal epithelium of the human prostate (5). 
The function of intermediate cells as well as their relation to ‘typically basal’ (K5/14) and 
‘luminal’ (K18) cells has, however, remained unclear. Isaacs and Coffey postulated that at 
least three cell types were present in the human prostate epithelium (13). Accordingly, the 
entire prostate epithelium is assumed to originate from a stem cell population with a long life 
span and a nearly unlimited proliferative capacity. This population gives rise to an 
intermediate cell group having a limited life span. By transient proliferation, intermediate 
cells amplify the number of secretory cells that only have a limited proliferative activity and 
eventually undergo terminal differentiation. Several animal and cell culture studies indicated 
that cells phenotypically resembling K5++/14++/18+ were progenitors of intermediate (K5/18) 
and differentiated cells (K18++) (7,11,12,32). Furthermore, intermediate cells seem to lack the 
cell cycle-dependent kinase inhibitor p27/kip1 in vivo, indicating that they indeed undergo 
proliferative activity (33). Intermediate cells have increasingly gained interest, because they 
are also encountered in human prostate cancer (5). Interestingly, the percentage of 
intermediate cells in prostate cancer is augmented upon androgen-deprivation (14). In 
extension to the hierarchic stem cell model of prostate epithelial differentiation, several 
groups postulated that intermediate cells are precursors of prostate cancer and target cells for 
its androgen-independent progression (5,13,33). Protein expression analysis might elucidate 
the functional characteristics of intermediate cells converging molecular and cell biological 
features during androgen-independent prostate cancer progression.
In this study, we demonstrated that intermediate cells (K5+/18++) in the luminal non- 
malignant prostate epithelium highly expressed the HGF receptor c-met, while more 
differentiated cells (K18++) were negative. Such a specific relation was not rendered in the 
basal epithelial compartment as both cell types (K5++/14++/18+ and K5++/18+) either expressed 
c-met or not. Information about the function of c-met in normal prostate epithelium is still 
limited. Cell lines derived from various organs respond to c-met activation by proliferation 
and differentiation leading to formation of complex structures (morphogenesis) in three­
dimensional matrices (34). Specifically, the SV40-immortalized cell line pRNS-1-1 derived 
from normal adult prostate epithelium responds to HGF stimulation by development of long 
ducts with distal branching when grown in collagen gels. As intermediate cells display high
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levels of c-met receptor they might be involved in epithelial morphogenesis supporting their 
putative role as transiently proliferating, amplifying cells in the hierarchic stem cell model of 
Isaacs and Coffey (13).
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Figure 4. Effect of HGF on prostate cancer cell line DU145 grown on matrigel. Before 
stimulation, DU145 forms compact epitheloid cell clusters (A). After stimulation with 25 
ng/ml HGF, elongations extend from the cell clusters that result in complex epitheloid 
connections between cell clusters (B).
The proto-oncogen c-met has been associated with several human malignancies and more 
aggressive behaviour of tumour cells in animal models. Over-expression of c-met was 
observed in human carcinomas derived from the colon, pancreas, lung and kidney (26,28-30). 
In prostate carcinoma, c-met over-expression was reported in 44 to 83% of the tumours
(20,27). We found a heterogeneous expression pattern of c-met in prostate carcinoma. Mild 
generalized c-met expression occured in all prostate tumours investigated, while a minority 
(1.7%) of malignant cells was identified with high c-met levels. Interestingly, c-met was 
highly expressed in malignant cells with an intermediate phenotype (K5+/18++), while more 
differentiated cells (K18++) only expressed c-met at low levels. The relative number of cells 
revealing high expression increased significantly during androgen-deprivation. Previously, it 
was shown that androgen-deprivation results in an enrichment of intermediate cells in prostate 
carcinoma (14). Therefore, increase of strongly c-met positive cells is consistent with 
enrichment of intermediate cells during androgen-deprivation therapy and implies their 
androgen-independent nature.
We analysed the effects of HGF on three prostate cancer cell lines to elucidate the cell 
biological activities of the HGF/c-met complex in intermediate cells. HGF strongly modified
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the growth pattern and invasive capacity of DU145, while such response was not encountered 
in LNCaP and PC3. Stimulation of DU145 resulted in cell scattering if cells were grown on 
glass, while elongations of cell clusters appeared in matrigel. Furthermore, HGF significantly 
enhanced invasion of DU145 in a matrigel invasion assay. It is interesting to compare the 
diverse effects of HGF on these three cell lines. LNCaP is an androgen-responsive cell line 
phenotypically resembling luminal cells (K18) that lacks c-met on mRNA level. Both 
androgen-independent cell lines DU145 and PC3 are characterized by an intermediate 
phenotype and express c-met on mRNA level (20). Although HGF does not affect the growth 
pattern of PC3, it enhances proliferation of this cell line (35). This indicates that the c-met 
receptor is indeed activated upon HGF stimulation but that lack of morphogenic response is 
due to downstream effectors. These results imply that intermediate cells in particular are 
targets of HGF-mediated prostate cancer invasion supporting the hierarchic stem cell concept 
of prostate carcinogenesis (5,13).
During progression, prostate carcinoma has a unique affinity to metastasize to bones. 
While autocrine activation of c-met does not seem to contribute to prostate cancer 
progression, Kmiecik et al. demonstrated that bone fibroblasts produce HGF (20,36). As 
prostate cancer metastases also express c-met, bone fibroblasts might mediate adhesion, 
invasion and progression at distant sites (27). The role of HGF/c-met signalling at metastatic 
sites as well as its capacity to modulate androgen-independent survival and hormone- 
refractory progression of prostate cancer still has to be determined.
In conclusion, the receptor c-met is highly expressed by a cell population 
phenotypically intermediate in between the putative stem cell and terminally differentiated 
cell compartments within the normal and malignant prostate epithelium. The ligand HGF 
induces motility, proliferation and invasion of various human malignant cell types by binding 
to its high-affinity receptor c-met. These data suggest that intermediate cells are particularly 
sensitive to HGF-mediated prostate carcinoma invasion, while differentiated cells only render 
mild invasive response. Interestingly, a keratin phenotype deviating from the pattern expected 
on the basis of differentiation has been described at “invasive fronts” of mucosal squamous 
cell carcinoma and transitional cell carcinoma of the urinary tract (37,38).
Activation of tyrosine kinase growth factor receptors has been implicated in androgen­
independent prostate cancer progression. We hypothesize that these receptors are 
preferentially expressed in intermediate cells as illustrated with c-met in this study. Activation 
of tyrosine kinase receptors might be responsible for selection of intermediate cells during 
androgen-deprivation therapy. Successive expansion of this intermediate cell population
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finally results in androgen-independent prostate cancer progression. This not only implies that 
intermediate cells are precursors of prostate carcinoma but also that they form new targets for
intervention in prostate cancer.
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Abstract
Epithelial cells in Proliferative Inflammatory Atrophy (PIA) appear to be cycling rapidly as indicated by 
expression o f Ki-67, and morphological transitions have been identified between PIA and high grade Prostate 
Intraepithelial Neoplasia (PIN). Many o f the atrophic epithelial luminal cells in PIA cells are candidates for 
intermediate cells based in part upon weak expression o f PSA and AR, high levels o f K8/18 and lack o f p63. The 
objective o f this study was to further clarify the phenotype o f the proposed intermediate cells in PIA and to 
quantitatively determine the level to which these intermediate cells preferentially occur in PIA lesions. 
Intermediate cells were immunohistochemically demonstrated using antibodies to K5, K14, K18 and c-met. 
Using radical prostatectomy specimens (N=15) the area fraction o f intermediate cells in normally differentiated 
prostate epithelium and PIA were quantified by a grid point counting method. Atrophic luminal cells o f PIA 
lesions expressed K5 in 39.2% +/- 7.4% o f cells compared to 2.4% +/- 2.3 % in normal epithelium (p<0.00001). 
Virtually 100% o f these cells were strongly positive for K18. K14 was only expressed in 3.0% +/- 3.2% o f the 
luminal cells, c-met was present in 44.1% +/- 14.1% o f luminal cells in PIA but only in 2.1% +/- 2.8% o f 
normal epithelium (p<0.00001). Luminal cells in PIA often co-expressed K5 and Ki-67. While p27/kip1 was 
strongly expressed in K5-negative differentiated cells in normal epithelium, staining was absent in many o f the 
cells in the luminal compartment o f PIA. We conclude that cells phenotypically intermediate between basal and 
secretory cells are enriched in PIA lesions. The finding o f a large number o f highly proliferating intermediate 
cells in PIA provides further support that these cells may serve as preferred target cells in prostate 
carcinogenesis.
Introduction
The phenotypic identification and cell biological characterization of epithelial stem cells has 
gained increasing interest in the study of human malignancies. Within rapidly proliferating 
tissues like bone marrow, intestinal tract and squamous epithelia, cell turn-over is governed 
by stem cells (1,2). Stem cells are generally characterized by a relatively undifferentiated 
state, while they have high proliferative capacity and a long life span. After mitosis, they give 
rise to an intermediate cell group that amplifies the divisions of the stem cells by undergoing 
additional rounds of cell division. The intermediate cells then mature towards terminally 
differentiated cells, which have very limited or no proliferative capacity.
Within the prostate epithelium basal and luminal cells can be distinguished based on 
their location, morphology and their phenotypic characteristics. Luminal secretory cells 
express high levels of Androgen-Receptor (AR), Prostate Specific Antigen (PSA), and 
Keratins (K) 8 and 18 (K8++/18++). Basal cells specifically display high expression of p63, 
bcl-2, Epidermal Growth Factor Receptor (EGFR), K5 and K14 (K5++/14++), while they 
contain low levels of AR, K8 and K18 (3). Two opposing stem cell models have been put
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forth in the development and maintenance of the prostate epithelium. Cell-kinetic studies in 
developing rats and analysis of proliferation in humans undergoing androgen-deprivation 
therapy have indicated, that both basal and luminal cells are independently capable of self 
renewal, suggesting distinct histogenic origins (4-6). Another model proposes that a subgroup 
of basal cells represents a stem cell population of the entire prostate epithelium. Independent 
of androgens, these stem cells give rise to intermediate cells that transiently proliferate and 
translocate towards the luminal cell compartment. Terminal differentiation finally contributes 
to the development of a large cohort of androgen-dependent luminal cells (7). Candidates for 
the amplifying cell population have been identified within the prostate epithelium, that are 
characterized by an intermediate phenotype between basal and luminal cells. First, in addition 
to the vast majority of basal cells with the K5++/14++/18+ phenotype, cells highly expressing 
K5 without K14 (K5++/18+) have been identified within the basal cell compartment 
(intermediate basal cells). The second intermediate cell type is characterized by co­
localization of K18 and the ‘basal cell marker’ K5 (K5+/18++) in the luminal layer 
(intermediate luminal cells) (8-10). Although fully differentiated prostate epithelial cells, 
expressing high levels of PSA and AR have only sporadically been produced as yet in vitro, 
human cell culture studies have indicated, that basal cells (K5++/14++/18+) can be progenitors 
of the intermediate (K5/18) as well as luminal epithelium (K18++), that express low levels of 
PSA (9,10). Although several phenotypic differences have been described in basal and 
luminal cells, only few studies have focused on the protein expression profile in the 
intermediate cell population. Cells with a morphologically intermediate position within multi­
layered prostate epithelium lack expression of the cell cycle-dependent kinase inhibitor 
p27/kip1 (11). Furthermore, we demonstrated that immunophenotypically intermediate cells 
within the luminal prostate epithelium highly express the Hepatocyte Growth Factor receptor 
c-met, which is involved in cell motility, morphogenesis, tissue regeneration and malignant 
transformation (12).
As the intermediate cell population was suggested to represent amplifying cells 
modulating the expansion and development of the prostate epithelium, it is pivotal to 
determine whether intermediate cells reveal proliferative activity. Approximately 70% of all 
proliferative activity in the human prostate is encountered within the basal cell layer (13). 
Interestingly, increased proliferation has been observed in atrophic glandular epithelium in the 
prostate (14-17). As glandular atrophy is often associated with chronic inflammation, De 
Marzo et al. proposed the term Proliferative Inflammatory Atrophy (PIA) for these lesions 
(17). In this study we provide evidence that intermediate cells are enriched in PIA lesions by
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analysis of various keratins and c-met expression. Using tyramide enhanced double-labelling 
immunofluorescence, we unambiguously demonstrate that many of the intermediate cells 
express the proliferation marker Ki-67 but not the cell cycle-dependent kinase (cdk) inhibitor 
p27/kip1.
Materials and Methods
Immunohistochemistry
Single label staining for c-met
Immunohistochemical expression of c-met was studied in 15 patients who had undergone 
radical retropubic prostatectomy for prostate carcinoma. All patient tissue samples were 
obtained with appropriate informed consent. Representative prostate sections were selected 
that contained PIA in routine hematoxylin/eosin (HE) stained sections. Sections (4 pm) of 
paraffin embedded tissue were dewaxed and rehydrated using xylene and ethanol, 
respectively. After immersion in 10 mmol/l citrate buffer (pH 6.0), the slides were subjected 
to microwave irradiation (600 W) for 4 min. Endogenous peroxidase activity was quenched 
for 30 min with 40% methanol containing 0.6% H2O2. After pre-incubation with 10% normal 
swine serum for 10 min, the slides were incubated with a dilution of 1:250 rabbit anti-human 
c-met antibody (C-28; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 hour at 37°C. 
The slides were washed in phosphate buffered saline (PBS) for 3 x 5 min followed by 
incubation with biotinylated donkey anti-rabbit (1:200) antibody for 30 min and conjugation 
with 1:100 avidin-biotin-peroxidase complex (Vectastain; Vector Laboratories, Burlingame, 
CA, USA) for 30 min. Chromogenic development resulted from incubation of slides with 
0.76% (w/v) 3,3’-diaminobenzidine tetrahydrochloride (DAB) containing 0.00075% (v/v) 
H2O2 for 10 min and was enhanced after exposure to a dilution of 0.5% CuS04/0.9% NaCl for 
5 min. All slides were counterstained with hematoxylin. Antibodies were diluted in PBS 
containing 5% bovine serum albumin (BSA) and incubations were performed in the dark at 
room temperature (r.t.) unless stated otherwise.
Single label staining for keratin 5
Dewaxed and rehydrated tissue sections (4 pm) were immersed in Antigen Unmasking 
Solution (Vector Laboratories) and steamed at 98°C (Black and Decker, Towson, MD, USA) 
for 14 min. Slides were pre-incubated with PBS containing Tween-20 (PBST) for 5 min, and
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were quenched for endogenous peroxidase using 3% hydrogen peroxide in dH20 for 7 min. 
After rinsing twice in PBS using a wash bottle, slides were incubated with a dilution of 
1:15000 of rabbit anti-mouse keratin 5 (#AF138; Covance Research Products, Denver, PA, 
USA) for 45 min at r.t. After washing, slides were incubated with the universal biotinylated 
secondary antibody (Vectastain Elite Kit), diluted 1:1000 in PBST with normal serum added 
for 30 min. Avidin-Biotin Complex - Horse Radish Peroxidase (ABC-HRP, Vectastain Elite 
Kit) was applied for 30 min. After rinsing DAB substrate (Vector) was applied for 5 min. 
Slides were counterstained with hematoxylin.
Single label staining for keratin 14
Sections were subjected to antigen retrieval (steaming) and quenching of peroxidase as for 
keratin 5. Slides were rinsed twice with PBS and were incubated in Protein Blocker 
(ChemMate Secondary Detection Kit; Ventana Medical Systems, Tucson, AZ, USA) for 5 
min. After rinsing twice, sections were incubated with the mouse anti-human keratin 14 
antibody (1:100; Innogenex, San Ramon, CA, USA) for 45 min at r.t. and then incubated for 
30 min in 3Ab-AB2 biotinylated secondary antibody. Slides were rinsed twice and then 
incubated in Avidin-Biotin Complex - Horse Radish Peroxidase (ABC-HRP) for 30 min. 
Slides were rinsed twice, incubated with DAB substrate according to ChemMate instructions 
for 5 min and counterstained with hematoxylin.
Immunofluorescence double-labelling for Ki-67/keratin 5 andp27/keratin 5
Sections were subjected to antigen retrieval (steaming) and endogenous peroxide block, as 
above for keratin 5. Slides were treated with the DAKO Biotin Blocking System (DAKO, 
Carpinteria, CA, USA) as per manufacturer’s protocol. After rincing twice in PBS, slides 
were treated with Protein Block #2 from the DAKO Catalyzed Signal Amplification (CSA) 
for 10 min. Slides were rinsed twice and reacted with either a 1:5000 dilution of mouse anti­
human p27/kip1 (Transduction Labs, San Diego, CA, USA) or a 1:100 dilution of mouse anti­
human Ki-67 (Zymed Laboratories, South San Francisco, CA, USA) in Antibody Dilution 
Buffer (Ventana Medical Systems, Tucson, AZ, USA) containing 1:15000 diluted rabbit 
polyclonal anti-keratin 5 (cker5; BabCO, Richmond, CA, USA) overnight at 4°C. After 
washing in PBST for 5 min, slides were incubated with the biotinylated secondary anti-mouse 
antibody (for detection of Ki-67 or p27/kip1) from the CSA Kit for 5 min. After rinsing twice, 
slides were incubated in Strepavidin-Peroxidase (CSA Kit) for 15 min at r.t followed by 
rinsing and incubation with biotinyl tyramide (CSA Kit) diluted 1:10 in Protein Block for 15
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min. Slides were incubated with Strepavidin Alexa Fluor 568 diluted 1:100 (to localize Ki-67 
or p27/kip1) mixed with goat anti-rabbit antibody conjugated directly to Alexa Fluor 488 
(Molecular Probes, Eugene, OR, USA) diluted 1:50 (to localize keratin 5) in Dulbecco’s 
PBX. Slides were rinsed twice and stained with DAPI (Sigma) diluted 1:3000 in dH20. Slides 
were mounted with Gelmount (Biomeda, Foster City, CA, USA).
Slides were imaged with a Zeiss Axioskop epifluorescence microscope equipped with 
short arc mercury lamp illumination (Carl Zeiss Inc., Thornwood, NY, USA) and appropriate 
fluorescence excitation/emission filters. Fluorescent images were captured with a cooled CCD 
camera (Micro MAX digital camera; Princeton Instruments, Trenton, NJ, USA) using IPLab 
Software (Scanalytics Inc., Fairfax, VA, USA).
Quantification and statistical analysis
Expression of K5, K14 and c-met was quantified within the luminal cell compartment of 
normal appearing, secretory epithelium and PIA. A total of 90 luminal cells was scored in 
each slide using a Weibel type II grid inserted into the ocular lens of an Olympus BX-40 light 
microscope, as previously reported (18,19). The percentages of positive cells in PIA and 
normal epithelium were statistically analysed using a Student t test. A probability value (p) of 
0.05 or less was considered significant.
Results
Morphology o f PIA lesions
PIA lesions, which encompass simple atrophy and the various forms of post-atrophic 
hyperplasia, were generally composed of a two-layered epithelium consisting of flat basal 
cells and cubical to low-columnar luminal cells; this is opposed to high-columnar cells that 
are characteristic of normal prostate epithelium. Figure 1a (Appendix). Luminal cells in PIA 
had scant basophilic cytoplasm and generally contained small round to oval nuclei localized 
in the center of the cell with inconspicuous to slightly enlarged nucleoli, while corresponding 
cells in normal epithelium had abundant pale cytoplasm, and basally localized nuclei without 
enlarged nucleoli. Figure 1b (Appendix). In contrast to normal epithelium, the epithelial lining 
in PIA generally did not form abundant papillary protrusions but was either rounded, or at 
times rather angular. The peri-glandular stroma in PIA lesions often showed mononuclear 
inflammatory infiltrates mainly composed of lymphocytes, macrophages, and occasionally
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plasma cells. At times, mononuclear cells, identifiable as macrophages, and/or 
polymorphonuclear neutrophils were prominent both intraluminally and within the 
epithelium. Corpora amylacea were often found in the lumina of PIA lesions.
Figure 2. Expression of c-met in normal appearing prostate epithelium and PIA. Luminal 
cells of normal epithelium sporadically express c-met (upper). The luminal epithelium of PIA 
reveals enhanced c-met expression (lower). B is amagnification of the box in A.
Enrichment o f intermediate cells in PIA lesions
Intermediate cells in the luminal prostate epithelium are characterized by co-expression of K5 
and K18, while K14 is absent (10). In normal appearing prostate epithelium K5 and K14 were 
mainly localized within the basal cell compartment. A number of the K5 positive basal cells, 
however, were negative for K14. Within the normal appearing prostate epithelium, a mean of 
2.4 ± 2.3% of luminal cells expressed K5, indicating sporadic existence of intermediate cells, 
while K14 was not observed in the luminal cell layer. In marked contrast to normal appearing 
epithelium, K5 was localized in 39.2 ± 7.4% of the luminal cells in PIA lesions. Figure 1 c,d 
(Appendix). The increase of K5 expression in PIA lesions was statistically significant 
(p<0.00001). In 3.0 ± 3.1% of luminal cells in PIA lesions, K14 was identified (p=0.003). 
Previously, we have shown that intermediate cells localized within the luminal prostate 
epithelium highly express the c-met receptor (12). In normal appearing prostate epithelium, c- 
met was localized in 2.1 ± 2.8% of luminal cells compared with 44.1 ± 14.1% in PIA lesions. 
This striking increase of c-met expression in PIA was statistically significant (p<0.00001). 
Figure 2.
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Proliferative activity o f  intermediate cells
Based on the high expression of Ki-67 as well as topo-isomerase II alpha and PCNA, PIA is 
considered an actively proliferating lesion (16,17). While the cells that stained positive for Ki- 
67 were generally localized in the luminal compartment of the atrophic glands, it remained 
unclear whether these cells also expressed K5, indicative of intermediate differentiation. To 
unambiguously determine whether intermediate luminal cells (those luminal cells expressing 
K5) in PIA lesions specifically show proliferative activity, we performed co-localization 
studies of K5 with Ki-67. In general, the majority of the Ki-67 positive cells in PIA were in 
the luminal layer and these cells co-expressed K5. Figure 3 (Appendix).
In a previous study we found that luminal cells in PIA often stained negative for 
p27/kip1, which was different than normal appearing prostate luminal cells, in which the vast 
majority stain strongly for p27/kip1 (17). To determine whether the luminal epithelial cells 
that express K5 in PIA show decreased p27/kip1 expression, we next performed co­
localization studies of K5 and p27/kip1. While the majority of luminal secretory cells in 
normal appearing non-atrophic epithelium (K5-negative) expressed p27/kip1, there were clear 
groups of luminal cells revealing K5 expression in PIA that lacked expression of p27/kip1. 
Figure 3 (Appendix).
Discussion
Human prostate epithelial cells with a phenotype intermediate between basal and secretory 
cells (intermediate cells) have gained increasing interest in the study of normal epithelial 
differentiation and malignant transformation of the human prostate epithelium, since they 
have been postulated to be the cell type of origin for prostate carcinogenesis (8,10,11). 
However, analysis of the biological characteristics of intermediate cells has been hampered by 
lack of techniques to identify this specific cell group and by the relatively low number of 
intermediate cells within the normal appearing prostate epithelium. Distinction of 
intermediate cells in the normal prostate epithelium warrants the application of 
immunohistochemical techniques, as neither cellular morphology nor topographic localization 
are specific for this cell population. Identification of intermediate luminal cells requires 
demonstration of K5 in the luminal cell layer, while the identification of intermediate basal 
cells requires the absence of K14 in the basal cell layer (10). Recently, we were able to better 
characterize these populations by employing a fluorescent triple-staining technique for the
74
Intermediate cells in PIA
identification of K5, K14 and K18 using directly labelled antibodies on frozen tissues and cell 
cultures. In the present study, we developed a method based on catalyzed deposition of 
biotinyl tyramide for fluorescent double-staining for the analysis of intermediate cell 
characteristics on formaldehyde-fixed, paraffin-embedded prostate tissues, which enables 
broad use and optimal histopathological analysis of prostate tissue. Using both standard 
immunohistochemistry for light microscopy and this dual-labelling technique, we now report 
that intermediate luminal cells are enriched in areas of atrophic prostate epithelium referred to 
as PIA. In addition, a subset of secretory intermediate cells in PIA (K5+/18++) expressed the 
proliferation marker Ki-67, while many of these cells lacked expression of the cdk inhibitor 
p27/kip1. These observations provide strong evidence that intermediate cells have 
proliferative capacity and support their putative role as amplifying cells in the prostate 
epithelium.
Isaacs and Coffey proposed a stem cell model in which the stem cell population gives 
rise to amplifying cells, that modulate the development of the entire epithelium by transient 
proliferation (7). During expansion this cell group putatively undergoes translocation from the 
basal towards the luminal cell compartment, while gradually shifting its gene-expression 
profile from stem cells towards terminally differentiated cells. In vitro, basal cells 
characterized as K5++/14++/18+ are indeed progenitor cells of intermediate (K5/18) as well as 
more differentiated cells (K18++) that lack expression of the basal keratins (9,10,20). 
Intermediate amplifying cells are believed to be androgen-independent for their survival. An 
increase of proliferative activity in the luminal cell layer during androgen-deprivation might 
therefore represent selection of transiently proliferating, intermediate cells rather than 
marking a distinct luminal stem cell population (3-6). Furthermore, intermediate cells highly 
express the receptor c-met (12). Activation of c-met is involved in complex cell biological 
processes, such as morphogenesis and tissue regeneration (21). Both dynamic processes are 
essentially associated with co-ordinated cell proliferation, migration and differentiation 
corresponding with the postulated role of intermediate cells in the prostate epithelium.
Glandular atrophy has been put forth as a regenerative lesion of the human prostate 
epithelium. While proliferation in the respective epithelium is highly increased, apoptotic 
activity maintains at normal levels (15-17). Furthermore, glandular atrophy is often 
accompanied by local chronic, and at times acute, inflammation and was therefore termed 
Proliferative Inflammatory Atrophy (17). As currently shown, the increased proliferative 
activity in PIA lesions represents an enrichment of intermediate cells, identified by K5 and c- 
met expression within the luminal epithelium. Although further phenotypic studies of
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intermediate cells are ongoing, the paradoxical expression of several basal cell markers within 
the luminal compartment of PIA might be explained by selection of intermediate cells (17). 
The sparse expression of K14 and lack of p63 staining in the luminal layer of PIA is further 
evidence that the luminal cells in PIA are not simply basal cells (22). The quantitative aspects 
of our current findings add utility for those who wish to study focal atrophic lesions in the 
human prostate. Based on the present findings, we propose that a lesion or even an individual 
acinus/duct can be defined as PIA if the majority of luminal cells are atrophic in appearance 
by HE (cubical and basophilic), and if > 10% of the luminal cells express “basal cell specfic” 
keratins—the latter can be defined by either K5, as in the present study, or using the more 
commonly used antibody 34PE12, which recogonizes K1, K5, K10 and K14.
Interestingly, in the original immunophenotypic and morphological descriptive study 
of PIA, we indicated that the luminal cells in PIA lesions lacked expression of basal specific 
keratins, as indicated by lack of staining for the 34PE12 antibody (17). In that set of 
experiments we used protease treatment for antigen unmasking. In the present study, we 
found that keratin 5, which is generally specific for basal cells, was indeed positive in many 
of the luminal cells in PIA, as was staining for 34PE12 (data not shown). A major difference 
in these studies is that in the present study we used steam heat without protease treatment for 
antigen retrieval. Since PIA cells generally lacked expression of K14 in the luminal layer, we 
propose that having K5 without its partner K14, renders the K5 susceptible to protease 
digestion in the luminal cells in PIA. This is consistent with studies of familial defects in 
single keratin genes, in which the heterodimeric partner protein that is encoded by wild type 
alleles is destabilized (23,24). This K5 protease susceptibility would explain why staining for 
34PE12 was not found in the luminal cells in PIA in the prior study (17). Indeed, in 
preliminary studies we find that steam heating followed by protease digestion will remove K5 
staining in luminal cells in PIA (W. R. Gage, A.M. De Marzo, unpublished observations).
In this study, we document that luminal cells within PIA lesions which appear to be 
regenerating, over-express the receptor c-met. Interestingly, levels of c-met are also raised in 
ulcerative colitis, acute pancreatitis and obstructive cholangiopathy (25-27). In these 
inflammatory lesions c-met might be involved in cell proliferation, migration and 
differentiation as part of a regenerative process. The receptor c-met is generally considered 
proto-oncogenic, because co-transfection of HGF and c-met in NIH3T3 cells gives rise to an 
aggressive and malignant phenotype (28). Furthermore, c-met is overexpressed in several 
human malignancies, such as pancreas, kidney and prostate carcinoma (28-32). In agreement 
with the stem cell model of Isaacs and Coffey, high expression of c-met together with their
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high proliferative activity put intermediate cells forth as putative progenitor cells for prostate 
carcinogenesis (7).
This stem cell model was recently updated wherein it was proposed that there are at 
least two types of intermediate, transiently amplifying cells. Basal intermediate cells were 
hypothesized to give rise to BPH and luminal intermediate cells were postulated to give rise 
to PIN and carcinoma (11). Although luminal intermediate cells represent a minority of the 
normally differentiated luminal epithelium, in this study we provide evidence that they are 
enriched in PIA lesions. The authors also postulated that the basal cells, by virtue of 
expression of high levels of genome protective enzymes, such as Glutathione S-Transferase 
PI (GSTPI), are protected from undergoing neoplastic transformation. Existence of chronic 
stress or persisting release of toxic agents by chronic inflammatory cells might subject the 
luminal intermediate cells in PIA to undergo genetic damage. While many of the luminal cells 
in PIA appear to have induced expression of GSTPI, not all of the cells have. It has therefore 
been proposed, that those luminal cells in PIA that lack GSTPI expression may be targets for 
genome damage and hence neoplastic transformation. Interestingly, Shah et al. indeed 
demonstrated changes of copy numbers of chromosome 8 in PIA, as occuring in PIN and 
adenocarcinoma (33).
In conclusion, we demonstrate that intermediate cells have proliferative activity 
supporting their histogenic role as amplifying cells in a hierarchic stem cell model of the 
prostate epithelium. The intermediate cell population is highly enriched in PIA lesions and 
might thus be susceptible to genetic damage. Further molecular and phenotypic 
characterization of intermediate cells should provide more definitive evidence as to whether 
intermediate cell populations in prostate epithelium are the true targets of carcinogenesis.
References
1. Potten CS, Morris RJ. Epithelial stem cells in vivo. J  Cell Science 1988 (Suppl); 1: 45-62
2. Potten CS, Loeffler M: Stem cells. attributes , cycles, spirals, pitfalls and uncertainties: lessons for and from 
the crypt. Development 1990; 110: 1001-1020
3. Van Leenders GJLH, Schalken JA. Stem cell differentiation within the human prostate epithelium: 
implications for prostate carcinogenesis. BJU 2001; 88(Suppl): 35-42
4. Evans GS, Chandler JA. Cell proliferation studies in rat prostate. I. The proliferative role of basal and 
secretory epithelial cells during normal growth. Prostate 1987; 10: 163-178
5. English HF, Santen RJ, Isaacs JT. Response of glandular versus basal rat ventral prostatic epithelial cells to 
androgen withdrawal and replacement. Prostate 1987; 11: 229-242
77
Chapter VI
6. Van der Kwast TH, Têtu B, Suburu ER, Gomez J, Lemay M, Labrie F. Cycling activity of benign prostatic 
epithelial cells during long-term androgen blockade: evidence for self renewal of luminal cells. J  Pathol 
1998; 186: 406-440
7. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989; 2(Suppl): 
33-50
8. Verhagen APM, Ramaekers FCS, Aalders TW, Schaafsma HE, Debruyne FMJ, Schalken JA. Colocalization 
of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 1992; 52: 6182-6187
9. Robinson EJ, Neal DE, Collins AT. Basal cells are progenitors of luminal cells in primary cultures of 
differentiating human prostate epithelium. Prostate 1998; 37: 149-160
10. Van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Demonstration of 
intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining 
confocal scanning microscopy. Lab Invest 2000; 80: 1251-1258
11. De Marzo AM, Meeker AK, Epstein JI, Coffey DS. Prostate stem cell compartments: expression of the cell 
cycle inhibitor p27/kip1 in normal, hyperplastic, and neoplastic cells. Am J  Pathol 1998; 153: 911-919
12. Van Leenders G, Van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Intermediate 
cells in normal and malignant prostate epithelium express c-met. implications for prostate cancer invasion. 
Prostate 2002; 51: 98-107
13. Bonkhoff H, Stein U, Remberger K. The proliferative function of basal cells in the normal and hyperplastic 
human prostate. Prostate 1994; 24: 114-118
14. Liavag I. Atrophy and regeneration in the pathogenesis of prostatic carcinoma. Acta Pathol Microbiol Scand 
1968; 73: 338-350
15. Feneley MR, Young MPA, Chinyama C, Kirby RS, Parkinson MC. Ki-67 expression in early prostate cancer 
and associated pathological lesions. J  Clin Pathol 1996; 49: 741-748
16. Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am J  Surg Pathol 
1998; 22: 1073-1077
17. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate. 
Implications for prostatic carcinogenesis. Am J  Pathol 1999; 155: 1985-1992
18. Parsons JK, Nelsons CP, Gage WR, Nelson WG, Kensler TW, De Marzo AM. GSTA1 expression in normal, 
preneoplastic, and neoplastic human prostate tissue. Prostate 2001; 49: 30-37
19. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, 
Isaacs WB. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not 
in prostate carcinoma. Cancer Res 2001; 61: 8617-8623
20. Hudson DL, O’Hare M, Watt FM, Masters JR. Proliferative heterogeneity in the human prostate: evidence 
for epithelial stem cells. Lab Invest 2000; 80: 1243-1250
21. Brinkmann V, Foroutan H, Sachs M, Weidner KM, Birchmeier W. Hepatocyte Growth Factor/Scatter Factor 
induces a variety of tissue-specific morphogenic programs in epithelial cells. J  Cell Biol 1995; 131: 1573­
1586
22. Parsons, J.K., Gage, W.R., Nelson, W.G. & De Marzo, A.M. p63 protein expression is rare in prostate 
adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 2001; 58: 619-24
78
Intermediate cells in PIA
23. Lloyd C, Yu QC, Cheng J, Turksen K, Degenstein L, Hutton E, Fuch E. The basal keratin network of 
stratified squamous epithelia: defining K15 function in the absence of K14. J  Cell Biol 1995; 129: 1329-1344
24. Jonkman MF, Heeres K, Pas HH, Van Luyn MJ, Elema JD, Corden LD, Smith FJ, McLean WH, Ramaekers 
FC, Burton M, Scheffer H. Effects of keratin 14 ablation on the clinical and cellular phenotype in a kindred 
with recessive epidermolysis bullosa simplex. J  Invest Dermatol 1996; 107: 764-769
25. Otte J-M, Kiehne K, Schmitz F, Folsch UR, Herzig K-H. c-met protooncogene expression and its regulation 
by cytokines in the regenerating pancreas and in pancreatic cancer cells. Scand J  Gastroenterol2000; 35: 90­
95
26. Liu Z, Sakamoto T, Ezure T, Yokomuro S, Murase N, Michalopoulos G, Demetris AJ. Interleukin-6, 
hepatocyte growth factor, and their receptors in biliary epithelial cells during a type I ductular reaction in 
mice: interactions between the periductal inflammatory and stromal cells and the biliary epithelium. 
Hepatology 1998; 28: 1260-1268
27. Kitamura S, Kondo S, Shinomura Y, Isozaki K, Kanayama S, Higashimoto Y, Minami T, Kiyohara T, 
Yasunaga Y, Ishikawa H, Ohtani T, Ishiguro S, Matsuzawa Y. Expression of hepatocyte growth factor and c- 
met in ulcerative colitis. Inflamm Res 2000; 49: 320-324
29. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH 3T3 cells 
induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 1994; 
91: 4731-4735
29. Ebert M, Yokoyama M, Friess H, Buchler MW, Korc M. Coexpression of the c-met proto-oncogene and 
hepatocyte growth factor in human pancreatic cancer. Cancer Res 1994; 54: 5775-5778
30. Natali PG, Prat M, Nicotra MR, Bigotti A, Olivero M, Comoglio PM, Di Renzo MF. Overexpression of the 
met/HGF receptor in renal cell carcinomas. Int J  Cancer 1996; 69: 212-217
31. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML. Hepatocyte growth 
factor and its receptor (c-met) in prostatic carcinoma. Am J  Pathol 1995; 147: 386-396
32. Pisters LL, Troncoso P, Zhau HE, Li W, Von Eischenbach AC, Chung LW. c-met proto-oncogen expression 
in benign and malignant human prostate tissues. J  Urol 1995; 154: 293-298
33. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Postatrophic hyperplasia of the prostate gland. Am J  
Pathol 2001; 158: 1767-1773
79
Chapter VI
80
Activation of c-met in DU145 identifies a2-Integrin as 
Intermediate Cell Marker in Human Prostate Epithelium
*
Geert J.L.H. van Leenders, Jun Luo , Tilly W. Aalders, Dirk J. Ruiter,
*
Jack A. Schalken, William B. Isaacs
*
The Brady Urological Institute, The Johns Hopkins University, 
School of Medicine, Baltimore, MD, USA
VII.
Submitted
81
Chapter VII
Abstract
Intermediate cells in the human prostate epithelium express high levels o f the Hepatocyte Growth Factor (HGF) 
receptor c-met. We analysed genes up-regulated after HGF (25 ng/ml) stimulation o f prostate cancer cell line 
DU 145 to identify novel markers for intermediate cells. Using cDNA micro-array analysis 14 genes were 
induced after HGF stimulation o f which four were confirmed by semi-quantitative RT-PCR. While a2-integrin 
(3.1x) and laminin-y2 (1.7x) mRNA revealed highest levels o f up-regulation, this was only accompanied by 
protein over-expression o f a2-integrin but not o f laminin-y2. Immunofluorescent double-staining demonstrated 
that K5-positive luminal intermediate cells in normal and malignant prostate epithelium co-expressed a 2- 
integrin but not laminin-y2. Because a2-integrin is involved in gradual epithelial differentiation as well as 
tumour invasion, these findings might support a hierarchic stem cell concept within the normal prostate 
epithelium in which intermediate cells are transiently proliferating amplifying cells, and indicate that 
intermediate cells are prone to invasion in prostate carcinoma.
Introduction
Prostate carcinoma presents as a heterogeneous neoplasm comprising extensive secretory 
exocrine and scattered neuro-endocrine differentiation. Initially, prostate carcinoma is 
considered an androgen-sensitive disease and therapeutic deprivation of androgens results in 
temporary regression of tumours. Within a period of several years most patients, however, 
show progression despite low androgen levels for which no satisfactory therapeutic options 
are currently available. Although prostate carcinoma is the most common malignancy among 
western men, its histogenic origin and shift towards androgen-independent disease are poorly 
understood.
Within normal human prostate epithelium at least four cell types are discriminated by 
their expression profile of specific intermediate filament proteins. Basal cells generally 
express high levels of both keratins (K) 5 and 14, together with low levels of K8 and 18 
(K5++/14++/18+) (1,2). Luminal cells are characterized by prominent co-localization of K8 and 
18 (K5714718++). Furthermore, two cell types have a keratin immunophenotype intermediate 
between basal and luminal cells. The first intermediate group is localized within the basal cell 
compartment but does not express K14 (K5++/14718+). The second population is recognized 
by low K5 expression within the luminal cell layer (K5+/14718++) (3).
Two opposing hypotheses try to explain the histogenesis of the prostate secretory 
epithelium. Distinct cell kinetic effects of androgen-withdrawal and re-administration on 
basal and luminal cells in rodents have led to the theory that the androgen-independent basal 
cell compartment and the androgen-sensitive luminal cell layer are derived from separate
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progenitor cells (4,5). In contrast, cell culture studies demonstrate that basal cells 
(K5++/14++/18+) have the capacity to differentiate towards luminal cells (K5714718++) 
indicating that the entire prostate epithelium is derived from a single stem cell population 
(3,6-8). In this hierarchic model, stem cells give rise to intermediate cells that by transient 
proliferation amplify the terminally differentiated luminal cell compartment, as was proposed 
by Isaacs and Coffey (9).
In prostate carcinoma, cells predominantly have the luminal-type keratin profile (K5- 
/14718++) revealing exocrine or neuro-endocrine differentiation (1,2,10). Although basal cell 
populations with the ‘stem cell’ phenotype (K5++/14++/18+) are absent, intermediate luminal 
cells characterized by expression of K5+/14718++ do occur in organ-confined as well as 
disseminated prostate carcinoma (11-14). In the hierarchic stem cell concept, intermediate 
cells are the progenitors of exocrine and neuroendocrine cells, hence, these intermediate cells 
might also play a pivotal role in prostate carcinogenesis (9,11,15,16). Functional 
characterization of intermediate cells in normal and malignant prostate epithelium can 
provide new clues for the definition of therapeutic targets directed towards prostate cancer.
Recently, we demonstrated that intermediate cells highly express the Hepatocyte 
Growth Factor (HGF) receptor c-met in normal and malignant prostate tissue (17). The 
androgen-independent prostate cancer cell line DU145 has high levels of c-met and HGF 
stimulation results in its scattering and enhanced invasive capacity (17-19). In this study, we 
analysed the gene-expression profile of DU145 upon HGF stimulation by cDNA micro-arrays 
to identify novel markers for prostate intermediate cells. We demonstrate that c-met activation 
induces a2-integrin and laminin-y2 on mRNA level, which is accompanied by up-regulation 
of a2-integrin but not laminin-y2 protein. Double-staining reveals high levels of a2-integrin in 
intermediate cells within the normal and malignant prostate epithelium. These findings 
support a hierarchic stem cell concept within the normal prostate epithelium, in which 
intermediate cells are transiently proliferating amplifying cells, and indicate that intermediate 
cells are prone to invasion in prostate carcinoma.
Materials and Methods 
Tissue collection and cell culture
Tissue samples were obtained from 14 patients undergoing radical prostatectomy for prostate 
carcinoma. All patients gave informed consent for use of the operation specimens for research
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purposes. Immediately after surgery, a 4-mm transverse section of the prostate was snap- 
frozen in liquid nitrogen and stored at -80°C until further use.
The human prostate cancer cell line DU145 (ATCC, Rockville, MD, USA) was 
maintained in a humidified incubator (95%O2; 5% CO2) at 37°C and covered with RPMI 
1640 media supplemented with 10% foetal bovine serum and 2 mM glutamine (GibcoBRL, 
Paisley, UK).
RNA extraction
DU145 cells were seeded on four T150-cell culture flasks (GibcoBRL, Paisley, UK). After 
adherence of the cells overnight, media were replaced by D-MEM/F-12 without phenol-red 
(GibcoBRL) supplemented with HEPES (15 mM), transferrin (5 pg/ml), insulin (5 pg/ml), 
Na2SeO3 (5 ng/ml) and bovine serum albumin (BSA 1 mg/ml). Cell cultures were incubated 
either with 0 or 25 ng/ml HGF (Sigma, Saint Louis, MO, USA) and media were replaced after 
48 hours. HGF stimulation induced scattering of DU145 while control cells formed epitheloid 
clusters. After 72 hours of incubation, total RNA was isolated, as described by Bittner et al. 
(20). Briefly, the aquous portion from the Trizol/chloroform (Life Technologies, Inc., 
Rockville, MD, USA) extraction step was mixed with an equal volume of 70% ethanol and 
purified using Qiagen RNeasy (Qiagen, Valencia, CA, USA) columns according to the 
manufacturer’s guide. RNA samples were subsequently concentrated using Microcon 100 
concentrators (Millipore, Bedford, MA, USA) and stored at -80°C until further use.
Array fabrication
A number of 6500 sequence-verified human cDNAs, representing 6112 unique genes (4573 
known genes) on the basis of Unigene build 128, were obtained under a Cooperative Research 
and Development Agreement with Research Genetics (kind gift of Dr. J. M. Trent, Cancer 
Genetics Branch, National Human Genome Research Institute, Bethesda, MD, USA). Printing 
of these cDNA clones was performed, as described previously (20). Briefly, amplified 
fragments from the clones were printed onto poly-L-lysine-coated glass slides. One week 
after printing, the arrayed slides were UV radiated to cross-link the DNA targets, treated with 
succinic anhydride to block poly-L-lysine, and boiled to denature DNA targets. A list of these 
cDNAs is available at http://www.nhgri.nih.gov/DIR/Microarray/Prostate_Supplement.
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Fluorescent labelling and Hybridization
Labelling of total RNA was achieved by direct incorporation of Cy5-dUTP or Cy3-dUTP 
(Amershan Pharmacia, Piscataway, NJ, USA) in a reverse transciptase reaction using 
anchored oligodeoxythymidylate primer (Genosys, The Woodland, TX, USA) and Superscript 
II reverse transcriptase (Life Technologies). Fluor-tagged cDNA was, subsequently, 
concentrated to the desired volume using Microcon concentrators (Millipore). Cy3-fluor- 
tagged cDNA of DU145 cells treated with 5 ng/ml HGF was mixed with Cy5-fluor-tagged 
cDNA of control DU145 cells and cohybridized on a micro-array. The complete procedure 
was performed in quatriplicate. Cohybridization of Cy5- and Cy3-fluor-tagged cDNA from 
control DU145 cells was used as a reference. Detailed labelling procedures are available from 
http://www.nhgri.nih.gov/DIR/microarray.
Data analysis
Hybridized slides were scanned using the Axon GenePix4000A scanner (Axon Instruments, 
Foster City, CA, USA) and images were processed using a collection of IPLab (Scanalytics, 
Inc., Fairfax, VA, USA) extensions developed at the Cancer Genetics Branch at National 
Human Genome Research Institute (21). For the identification of potential HGF-induced 
intermediate cell markers mean levels of over-expressed genes were compared to control 
DU145. An exceeding rate of >0.95 was used for further verification of potential intermediate 
cell markers.
RT-PCR analysis
Total RNA was isolated using Trizol reagent according to the manufacturer’s instructions 
(Invitrogen, Inc., Carlsbad, CA, USA). Two pg of total RNA were DNase-I treated and cDNA 
was synthesized using Superscript MMLV-reverse transcriptase (RT) (Invitrogen, Inc.). The 
synthesis of cDNA was quantified by the measurement of [a-32P]dATP incorporation (~3000 
Ci/mmol; Amersham, Amersham, UK) in a parallel RT-reaction. Ten nanograms of cDNA 
were used for a PCR reaction using gene-specific primers. Table 1. The cDNA was amplified as 
follows: 45’’, 98oC/ 45’’, 60oC / 45’’, 72oC/ Ncycles/ 10', 72oC. To verify the quality of the cDNA 
synthesized, control reactions were performed using primers derived from the ^2-microglobulin 
housekeeping gene. The amplification was as follows 1’, 98oC/ 1’, 58oC/ 1’, 72oC/ 35 cycles/ 10', 
72oC (22). PCR products were analysed by agarose gel electrophoresis (Molecular Analyst; 
BioRad Laboratories, Hercules, CA, USA).
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Table 1. Primers and cycle number for PCR amplification
Gene Cycli Forward primer (5’ to 3 ’) Reverse primer (5’ to 3’)
Leukemia inhibitory factor receptor 24 ATGGGAAGACATTCCTGTGG CGTTTCCGATAGCAAAGGAT
Topo-isomerase IIa 22 CGTGTCAGACCTTGAAGCTG CTTGCTTGTGACTGCTTTCG
Laminin-y2 22 GTATGGGCAATGCCACTTTT AGAGAGGCCAGTCCCTTTTC
Janus kinase 1 22 GAAGGTTGAGCTCTGCAGGT CAAGTCCCGGTGAACGTATT
c-m et 22 GGATGGCTTTGGAAAGTCTG GGATACGGAGCGACACATTT
a2-Integrin 26 CAGGCACACCAAAGAATTGA GAAGAAGCCGAGCTTCCATA
Interleukin-13 receptor 22 CTTGTTTCATGGTCCCTGGT TCCTCCTTGGTTTGCTTCTC
Neuropilin 1 22 CGAAAATCAGAAGGGCAAAG ATCCAGGTCTGCTGGTTTTG
Tight junction protein 2 22 AGCCGAGCCGATGTGTATAG GGTCTTCCCGACTTTTCCTC
LI-cadherin 36 TACAAGTGGTGGCCACAGAA T GCGGAT C AAGAC GAC AT AC
P2-microglobulin 35 AGCAGAGAAT GGAAAGT C AAA TGTTGATGTTGGATAAGAGAA
Protein expression o f a2-integrin and laminin-y2 in DU145
The cell line DU145 was seeded on 8-wells glass (GibcoBRL) at a density of 5 x 103 cells/ 
well. After adherence of the cells overnight, media were replaced by supplemented D- 
MEM/F-12 and incubated with 25 ng/ml HGF. After incubation for 24, 48 or 72 hours, slides 
were acetone-fixed at -20°C, air-dried and incubated with a mixture of either mouse anti­
human a2-integrin (Gi-14; 1:400; kind gift of Dr. E. Klein, University of Ulm, Germany) or 
mouse anti-human laminin-y2 (1:100; Chemicon, Inc., Temecula, CA, USA), together with 
rabbit anti-human c-met (C-28; 1:250; Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
After washing in phosphate buffered saline (PBS), slides were incubated with a dilution of 
1:200 goat anti-mouse Ig labelled with Alexa™ 594 (Molecular Probes, Eugene, OR, USA) 
for visualization of a2-integrin or laminin-y2, and 1:200 goat anti-rabbit Ig labelled with 
Alexa™ 488 for c-met during 30 min. The slides were mounted with fluorescent mounting 
medium (DAKO, Glostrup, Denmark) and analysed using confocal laser scanning microscopy 
(CLSM; The Confocal System LEICA TCS NT, Leica, Wetzlar, Germany). All dilutions were 
made in PBS/1% bovine serum albumin (BSA) and incubations were performed in the dark at 
room temperature (r.t.).
FACS analysis o f  a2-integrin in DU145
After adhesion of DU145 cells overnight in T75 flasks, the culture medium was changed to 
supplemented DME/F12 medium and incubated with 25 ng/ml HGF for 24, 48 and 72 hours, 
respectively. Cells were harvested after incubation with 1 mM EDTA for 20 minutes, washed 
in 0.9% NaCl and labelled with 50 pl mouse anti-human a2-integrin (Gi-14; 1:400) for 20 
min at 4°C. The cells were washed and incubated with 100 pl goat anti-mouse Ig conjugated
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with Alexa™ 488 (1:200; Molecular Probes) for 20 min. FACS-analysis (Beckman Coulter, 
Inc., Fullerton, CA, USA) was performed on paraformaldehyde-fixed cells.
Double-staining o f K5/a2-integrin and K5/laminin-y2 in prostate tissue
Cellular localization of a2-integrin and laminin-y2 in prostate tissue was analysed using 
immunofluorescent double-staining combining K5/a2-integrin and K5/laminin-y2. Cryostat 
sections of 4 pm were fixed in acetone at -20°C for 10 min, air-dried overnight and incubated 
either with anti- a2-integrin or anti- laminin-y2 for 60 min at r.t. After washing in PBS, slides 
were incubated with a dilution of 1:200 goat anti-mouse Ig labelled with Alexa™ 488 
(Molecular Probes) for 30 min. Free Ig-binding sites of the goat anti-mouse Ig were blocked 
with 10% normal mouse serum during 10 min. After extensive washing, the slides were 
incubated for 1 hour with a 5 pg/ml dilution of anti-human K5 antibody (RCK103) directly 
conjugated with Alexa™ 546, as described previously (3). Slides were finally incubated with 
TO-PRO (1:100; Molecular Probes, Eugene, OR, USA) for 5 min to visualize nuclei.
Indirect immunohistochemistry o f prostate tissue
Cryostat sections were acetone-fixed, air-dried overnight and either incubated with anti- a2- 
integrin or anti- laminin-y2. The slides were washed in PBS for 3 x 5 min followed by 
incubation with biotinylated sheep anti-mouse (1:200) and conjugation with 1:100 avidin- 
biotin-peroxidase complex (Vectastain; Vector Laboratories, Burlingame, CA, USA) for 45 
min. Chromogenic development resulted from incubation of slides with 0.76% (w/v) 3,3’- 
diaminobenzidine tetrahydrochloride containing 0.00075% (v/v) H2O2 for 10 min and was 
enhanced after exposure to a dilution of 0.5% CuSO4/0.9% NaCl for 5 min. All slides were 
counterstained with hematoxylin.
Results
Gene expression analysis
Micro-array analysis of DU145 after HGF stimulation revealed 14 cDNA’s up-regulated 
when compared to control hybridization: tight junction protein 2 (3.5x), Janus Kinase 1 
(2.7x), c-met (2.5x), a2-integrin (2.1x), endothelin converting enzym 1 (2.1x), contactin 1 
(2.1x), leukemia inhibitory growth factor receptor (2.0x), laminin-y2 (1.9x), neuropilin 1
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(1.7x), a-integrin binding protein 63 (1.7x), LI-cadherin (1.5x), topo-isomerase IIa (1.5x), 
interleukin-13 receptor (1.4x), STAT6 (1.4x).
24 24 48 48 72 72 hours 
G 25 G 25 G 25 ng/ml HGF
a2-integrin
laminin-y2
ß2-microglobulin
Figure 1. RT-PCR validation of a2-integrin and laminin-y2 mRNA upon HGF stimulation of 
DU145 for 72 hours. Both a2-integrin (3.1x) and laminin-y2 (1.7x) are up-regulated by HGF. 
P2-microglobulin was used for control of total mRNA quantity
Semi-quantative RT-PCR
Expression of 11 mRNA’s up-regulated at cDNA micro-array analysis were verified using 
RT-PCR. Janus kinase 1, c-met and tight junction protein 2 were excluded from further study 
because they apparently revealed multiple PCR-products with the primersets chosen. Semi­
quantitative RT-PCR of cDNA over-expressed at micro-array confirmed apparent up- 
regulation of a2-integrin (3.1x) and laminin-y2 (1.7x), without significant changes in 
leukemia inhibitory factor receptor (1.2x), LI-cadherin (1.2x), neuropilin-1 (1.0x), topo- 
isomerase IIa (0.9x), and interleukin-13 receptor (0.9x). Sequence analysis of PCR products 
confirmed their representation of the target genes (data not shown). Based on these results a2- 
integrin and laminin-y2 were considered as potentially useful markers for the intermediate 
amplifying cell. Their level of mRNA up-regulation was similar at 24, 48 and 72 hours, 
suggesting they are consistently expressed in intermediate cells upon c-met activation. Figure 
1.
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a2-Integrin protein is up-regulated in HGF-stimulated DU145
To determine whether mRNA up-regulation resulted in enhanced protein expression of a2- 
integrin and laminin-y2, stimulated DU145 cells were immunohistochemically compared with 
control cells. Immunofluorescent double-staining of c-met and a2-integrin showed weak 
punctuated expression of c-met in all cells combined with moderate to high membranous 
expression of a2-integrin. Although the expression level of c-met was similar in both HGF- 
stimulated and control cells, HGF-treated cells revealed increased membranous a2-integrin 
expression. It seemed that a2-integrin expression was not equally enhanced in every cell, but 
more cells expressed a2-integrin at high levels. This observation was confirmed by FACS- 
analysis of a2-integrin labelled DU145 cells. Figure 2 (Appendix).
Immunofluorescent staining of laminin-y2 demonstrated weak to moderate, 
membranous expression in all cells, which did not significantly change after HGF stimulation 
(not shown). This indicates that induction of laminin-y2 mRNA is not accompanied by higher 
protein levels in DU145 cells.
a2-Integrin expression in PIA lesions
Histopathologic evaluation of frozen prostate tissues revealed a heterogeneous composition of 
normal glandular epithelium, fibro-muscular stroma, Prostatic Intraepithelial Neoplasia (PIN), 
adenocarcinoma and local areas of Proliferative Inflammatory Atrophy (PIA), which is 
characterized by atrophic glands with a cubical luminal cell layer often associated with 
inflammation (23). These lesions are thought to represent regenerative prostate glands 
enriched for cells with an intermediate phenotype. Basal cells of normal-, PIN- and PIA- 
processes consistently expressed a2-integrin, while laminin-y2 was localized within the 
basement membrane proximal to the basal cell layer. High-columnar luminal cells of normal 
glandular prostate epithelium and PIN neither showed expression of a2-integrin nor laminin- 
y2. Interestingly, cubical luminal cells of PIA lesions often demonstrated membranous 
localization of a2-integrin but not laminin-y2 indicating the expression of a2-integrin in 
intermediate cells. Prostate adenocarcinoma revealed no (n=2), low (n=10) or strong (n=2) 
membranous expression of a2-integrin. Membranous expression of laminin-y2 was negative 
(n=8), low (n=4) or strong (n=1). Figure 3.
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Figure 3. Immunohistochemical expression of a2-integrin and laminin-y2 in the prostate. A-C 
a2-Integrin is expressed in both basal and luminal epithelium of PIA (A,B). In prostate 
carcinoma a2-integrin is locally expressed. Note basal expression in a pre-existent grand (C). 
D,E Laminin-y2 is encountered at the interface of basal epithelium and basement membrane, 
but not in luminal cells of PIA (D). The picture was taken from the area depicted in A. 
Moderate expression of laminin-y2 in adenocarcinoma (E; arrowheads).
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Intermediate cells express a2-integrin protein
Immunofluorescent double-staining was performed to analyse expression of a2-integrin and 
laminin-y2 in luminal, immunophenotypically intermediate cells (K5+/14-/18++). Expression 
of laminin-y2 was restricted to the basement membrane and did not co-localize with K5- 
positive luminal cells. Figure 4 (Appendix). As expected the basal cell compartment co­
localized K5 and a2-integrin. Additionally, a2-integrin was expressed in cubical K5-positive 
luminal cells but lacked in K5-negative differentiated cells. Locally, co-expression of K5 and 
a2-integrin was observed in prostate carcinoma. Figure 5 (Appendix). These results 
demonstrate that intermediate cells in normal and malignant prostate epithelium express a2- 
integrin.
Discussion
Within intact prostate epithelium, intermediate cells are characterized by a basal-luminal 
keratin immunophenotype. The first evidence for the biological role of intermediate cells 
came from androgen-deprivation and re-administration in male rats, in which K5-positive 
cells appeared within the luminal compartment of the regenerating prostate (24). Analysis of 
complex keratin expression profiles then further identified intermediate cells in the human 
prostate epithelium (11,25). Application of triple-immunofluorescent keratin staining 
ultimately confirmed the existence of at least four cell populations within the non-malignant 
human prostate epithelium: 1) K5++/14++/18+-basal cells, 2) K5++/14'/18+-basal cells, 3) 
K5+/14'/18++-luminal cells and 4) K5'/14'/18++-luminal cells (3). The localization and 
phenotype of the second and third population makes them candidates for the intermediate 
transiently proliferating compartment.
The determination of cell biological functions of intermediate cells is hampered by the 
lack of appropriate cell culture models in which this subpopulation can be traced, and the 
practical necessity of double-labelling techniques for their identification. Although 
independent in vitro studies have identified K5++/14++/18+-basal cells as progenitors of the 
luminal cell population, avowed exocrine differentiation characterized by PSA secretion as 
occurs in vivo has not been sustained yet (3,6-8). De Marzo et al. indicated that intermediate 
cells are proliferating cells by their lack of cell cycle-dependent kinase inhibitor p27/kip1 
(16). This and other groups, further, identified atrophic glandular lesions within the prostate 
as locations enriched for intermediate cells by the high expression of “basal markers” bcl-2,
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GSTPI, PCNA and Ki-67 within the luminal epithelium together with low androgen-receptor 
levels (23,26,27). Altogether these results suggest that intermediate cells are proliferating 
cells that amplify an expansive luminal epithelium in physiologic homeostasis and pathologic 
tissue regeneration.
The observation of high c-met receptor levels within intermediate luminal prostate 
epithelium led us to the use of cDNA micro-array analysis for identification of down-stream 
c-met effectors as novel intermediate cell markers (17). Micro-arrays are powerful tools to 
analyse gene-expression profiles in tissues and cell culture. However, interpretation of the 
expression profiles obtained demands validation of the results at the protein expression level. 
The androgen-independent prostate cancer cell line DU145 is characterized by its 
intermediate cell phenotype (K5+/18++) and high expression of c-met (17-19). Upon HGF 
stimulation, DU145 shows morphological scattering and an increased invasive capacity. This 
report identified a2-integrin and laminin-y2 as down-stream effectors of c-met activation and 
potential markers for intermediate cells, based on cDNA micro-array validated by semi­
quantitative RT-PCR analysis. While induction of a2-integrin mRNA was accompanied by 
protein over-expression, protein levels of laminin-y2 did not increase.
These results provide indications for the biological functional role of c-met and its 
down stream effects such as induction of a2-integrin. Integrins are heterodimeric, 
transmembrane receptors implicated in cell-matrix interaction and cell-cell adhesion. In 
particular, a2p1-integrin mediates cellular adhesion to collagen I and collagen IV. Within the 
prostate a2p1-integrin levels are highest at the junction of basal cells and basement 
membrane, corresponding with cell-matrix attachment at this site (28,29). The expression of 
a2p1-integrin at baso-lateral cell membranes, further suggests a role in intercellular adhesion. 
Various self-renewing epithelial tissues demonstrate a gradient of a2p1-integrin expression 
correlating with the state of differentiation i.c. high expression in stem cells and absence in 
terminally differentiated cells. In skin a2p1-integrin declines in suprabasal layers, while in 
colon a2p1-integrin is strongest in crypts and diminishes directing towards the mucosal 
surface (30,31). The localization of a2-integrin in the basal cell compartment in this study 
corresponds with the expression of a2p1-integrin at attachemt sites of the basal cells to the 
basement membrane. Additionally, luminal epithelial cells in PIA lesions demonstrate high 
levels of a2-integrin at their baso-lateral cell membrane, while high-columnar cells in 
differentiated luminal epithelium are negative. The localization of a2-integrin in PIA lesions 
indicates that intermediate cells highly express this integrin, which was confirmed by 
immunofluorescent double-staining. In accordance with the gradual decline of a2p1-integrin
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from stem cells towards terminally differentiated cells in skin and colon, 
immunophenotypically intermediate cells might represent amplifying cells in prostate 
epithelial differentiation. Collins et al. indeed demonstrated subtle gradients of a2p1-integrin 
expression in basal cells using directly labelled antibodies (8). The subpopulation of basal 
cells with highest a2p1-integrin levels had the capacity to restore complete gland formation 
when grafted into athymic male mice. Although the immunostaining technique used in this 
study apparently was not suitable to assess subtle a2-integrin expression gradients, these 
results support a hierarchic stem cell concept, in which stem cells in the basal cell layer give 
rise to intermediate cells that amplify the population of terminally differentiated, luminal cells
Laminins, a family of extracellular glycoproteins expressed in basement membranes, 
are composed of three different polypeptide chains (a, p, y) forming a cruciform structure. 
Differential combination of the these subunits results in laminin-isoforms with various, 
uncharacterized biological functions. Laminin-y2 is a subunit of laminin-5 (laminin a3p3y2) 
which is a hemidesmosomal protein involved in cell-matrix interaction (32). In human 
prostate epithelium laminin-5 expression is restricted to the basement membrane, while high- 
columnar differentiated cells as well as cubical PIA luminal cells were negative contrasting 
with the expression of a2-integrin. Although laminin-y2 mRNA induction is not accompanied 
by protein over-expression in this study, keratinocyte migration intriguously requires 
interaction of a2p1-integrin with the y2-subunit of laminin-5 (33).
Prostate carcinoma is a heterogeneous malignancy in which at least three cell types 
can be discriminated. The predominant cell population in prostate carcinoma corresponds 
with the differentiated, exocrine luminal cell (K5714718++, PSA+). Furthermore, scattered 
neuro-endocrine and intermediate cells (K5+/14718++) are present in prostate carcinoma. We 
demonstrate that scattered intermediate cells in prostate carcinoma express high levels of 
a2p1-integrin, while its clustered localization indicates the existence of additional regulatory 
pathways of a2p1-integrin (29). In contrast with other groups, laminin-y2 was identified in a 
subset of prostate carcinomas and in one case was even strong (34,35). Although laminin-y2 
mRNA is present in malignant prostate epithelium and cell lines, protein expression usually 
does not occur (34). In DU145 laminin-y2 protein is synthesized but not secreted by the cells 
(36). While the functional state of laminin-y2 expression by prostate adenocarcinoma remains 
unresolved, it is intriguing that laminin-y2 is specifically expressed at the invasive front of 
esophageal and gastric carcinomas (37,38). As stimulation of c-met results in enhanced 
invasive capacity of prostate carcinoma in vitro, we hypothesized intermediate cells to form
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cellular invasive fronts in prostate carcinoma (17). Expression of a2pi-integrin mediates 
invasion and metastatic dissemination in gastric, breast, ovarian and oral carcinoma models 
(39-42). The expression pattern of a2-integrin suggests altered matrix-adhesion at the level of 
intermediate cells in prostate carcinoma, possibly modifying their invasive capacity. Further 
analysis of HGF-mediated a2-integrin and laminin-y2 up-regulation in prostate carcinoma 
might reveal new insights in the role of intermediate cells in prostate carcinogenesis and 
progression.
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Abstract
Within the human prostate epithelium four cell populations are discriminated by their expression o f keratins (K). 
While basal cells co-localize K5 and K14 combined with low  levels o f K18 (K5++/14++/18+), luminal cells highly 
express K18 (K18++). In addition, two intermediate subpopulations are characterized either by basal K5++/18+- 
or luminal K5+/18++- expression. The entire prostate epithelium is putatively derived from a basal stem cell 
population. Stem cells give rise to intermediate cells that transiently proliferate and mature towards 
differentiated luminal epithelium. Within prostate carcinoma luminal exocrine, neuro-endociine and 
intermediate cells are distinguished. Intermediate cells have been postulated as progenitors for prostate 
carcinogenesis and targets for androgen-independent tumour progression. Androgen-independency is associated 
with an enrichement o f intermediate cells and over-expression o f peptide growth factor receptors. Targeting 
intermediate cells by inhibition o f their peptide growth factor receptors, therefore, offers novel treatment 
modalities for prostate cancer.
Introduction
Within the human prostate epithelium morphologically two cell populations can be 
discriminated. The most prominent cell population consists of high-columnar luminal cells 
revealing secretory activity, while stretched basal cells adhere to the basement membrane. 
Two opposing hypotheses try to explain the cellular homeostasis of the human prostate 
epithelium. The observation of proliferative activity in both basal and luminal cells in 
androgen-deprivation studies of adult rats indicated self renewal of both cell compartments 
(1,2). Isaacs and Coffey, however, postulated that the entire prostate epithelium is derived 
from a stem cell population with a long life span and nearly unlimited proliferative capacity, 
residing within the basal cell compartment (3). Stem cell duplication gives rise to one copy 
stem cell (self renewal) and one progenitor cell with a relatively short life span and limited 
proliferative capacity. By transient proliferation, this cell population amplifies the prostate 
epithelium eventually resulting in terminally differentiated cells that are destined to undergo 
apoptosis. This model is in line with hierarchic stem cell concepts of self-renewing tissues, 
such as skin and intestine (4,5).
While disturbances of stem cell differentiation were initially included in the 
pathogenetic concept of benign prostate hyperplasia (BPH), the observation of putative 
amplifying cells in adenocarcinoma suggested their involvement in prostate carcinogenesis as 
well (3,6). Prostate cancer is the most common malignancy among western men (7). While 
the clinical course of prostate cancer is variable, radical prostatectomy is currently still the 
standard treatment for organ-confined disease. During a prolonged period pharmacological or
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surgical androgen-deprivation has been applied for metastasized prostate cancer. After initial 
remission, however, most patients eventually experience tumour progression in spite of low 
androgen-levels. Currently, no satisfactory therapeutic options are available for the recurrence 
of androgen-independent prostate carcinoma.
During the last decade, an increasing amount of data has been gained supporting a 
hierarchic stem cell concept of the human prostate epithelium. In this report, the implications 
of cellular differentiation for prostate epithelial homeostasis and carcinogenesis are reviewed 
together with the subsequent importance for the treatment of prostate cancer.
Markers of Prostate Epithelial Differentiation
Immunophenotypic keratin (K) expression analysis has gained validity in the study of prostate 
epithelial differentiation. Keratins belong to the group of intermediate filament proteins 
interlacing the cytoskeleton by heterodimeric interaction and polymerization (8). As in all 
simple epithelia, prostate luminal cells express high levels of K8 and 18 (K8++/18++) (9-11). 
Basal cells are characterized by expression of K5 and 14 in the presence of low K8 and 18 
levels (K5++/14++/18+) (12-14). In 1988, an additional cell population co-localizing K5 and 
K18 within the luminal epithelium was identified in rats (15). As this cell population had an 
immunophenotype intermediate between basal and luminal cells, it potentially represented the 
amplifying cell type, originally described by Isaacs and Coffey, which was further supported 
by its appearance in androgen-induced regeneration of the prostate epithelium (3). By step- 
section analysis and immunofluorescent dual/triple-staining, eventually two intermediate cell 
types were distinguished within the human prostate epithelium. The first intermediate cell 
type is characterized by expression of K5 in the absence of K14 (K5++/18+) in the basal 
compartment, while a second intermediate subpopulation co-localizes K5 and K18 (K5+/18++) 
within the luminal epithelium (6,14,16,17).
Prostate exocrine activity is restricted to the luminal epithelium which secretes 
Prostate Specific Antigen (PSA) and Prostate Acid Phosphatase (PAP) into the glandular 
lumina. Additionally, neuro-endocrine cells are scattered throughout the prostate epithelium 
which can be recognized by paracrine secretion of neuro-peptides and hormones. The 
physiological function of neuro-endocrine cells largely remains unknown, but they potentially 
modulate proliferation and differentiation in adjacent exocrine cells (18).
99
Chapter VIII
TD exocrine cells
TD neuro-endocrine cells
Expression
level
Location
Figure 1. Classic stem cell differentiation model of the prostate epithelium A stem cell 
population (K5++/14++/18+) in the basal cell layer gives rise to intermediate basal cells 
(K5++/18+). By proliferation and translocation a second intermediate cell type (K5+/18++) 
arises in the luminal cell layer. This intermediate cell population transiently proliferates and 
shows maturation towards terminally differentiated (TD) luminal cells (K18++). During 
differentiation, intermediate cells either obtain exocrine (PSA) or neuro-endocrine (ChA) 
characteristics.
Dual-labelling of keratins and neuro-endocrine peptides demonstrated neuro-endocrine 
differentiation in subsets of basal (K5++/14++/18+), intermediate (K5/18) as well as luminal 
(K8++/18++) cells, while Bonkhoff et al. were also able to identify sporadic PSA expression in 
epithelial cells reacting with the antibody 34PE12 (anti-K1, K5, K10, K14) (19,20). The
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existence of both exocrine and neuro-endocrine differentiation among distinct epithelial 
subpopulations suggests that they have a mutual histogenic relationship.
Strong evidence for a hierarchic stem cell model comes from in vitro studies of 
prostate epithelial differentiation. The initial cell population expanding in culture corresponds 
with a basal phenotype (K5++/14++/18+). After confluence, additional cell populations are 
observed with an intermediate (K5/18) and luminal (K8++/18++) phenotype (14,21,22). Collins 
et al. further demonstrated that basal cells with high levels of a2p1-integrin had the capacity 
to restore prostate epithelial glands when grafted into male nude mice (23). The successive 
appearance of epithelial cell types in vitro and in vivo, indicates that the entire prostate 
epithelium is derived from one stem cell population. Figure 1.
Recently, we were also able to identify a2-integrin in intermediate cells of the normal 
human prostate epithelium (Van Leenders et al., thesis chapter VII). Several self-renewing 
epithelial tissues demonstrate gradual decline of a2p1-integrin from stem cells towards 
terminally differentiated cells. In skin a2p1-integrin declines in suprabasal layers, while in 
colon a2p1-integrin is strongest in crypts and diminishes directing towards the mucosal 
surface (24,25). In accordance, intermediate cells might represent amplifying cells of prostate 
epithelial differentiation.
Stromal-Epithelial Interactions
Development and homeostasis of the prostate glandular epithelium is dependent on stromal- 
epithelial interactions (26,27). Prostate stromal cells deposit a three-dimensional matrix in 
which the glands are embedded, and undergo paracrine interaction with the epithelial cells. 
Numerous growth factors are involved in stromal-epithelial interaction, such as Epidermal 
Growth Factor (EGF), Transforming Growth Factor-a (TGFa), Fibroblast Growth Factors 
(FGF), Insuline Growth Factors (IGF), TGFp and Hepatocyte Growth Factor (HGF) (28-31).
Epidermal Growth Factor and Transforming Growth Factor-a are well-known 
mitogens for prostate epithelium in vitro (32). In the human prostate epithelium, the effect of 
both EGF and TGFa is mediated by the EGF-receptor (EGFR) localized within the basal cell 
compartment (33,34). The reduction of EGF-levels upon castration indicates that EGF 
secretion is under control of the androgen-receptor (AR) and indirectly modulates epithelial 
cell proliferation upon androgen re-administration (35).
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Hepatocyte Growth factor/ Scatter Factor is involved in various biological processes as 
proliferation, migration, angiogenesis and tissue regeneration, as well as malignant 
transformation. In three-dimensional collagen gels, HGF stimulation of epithelial cell cultures 
derived from various organs results in the formation of complex structures reminiscent of the 
original organ morphology (morphogenesis) (36). As morphogenesis requires balanced 
proliferation and differentiation, we hypothesized intermediate cells to express high levels of 
the HGF receptor c-met. Double-staining (K5/c-met) indeed confirmed the expression of c- 
met in basal as well as intermediate human prostate epithelium (37,38). Unfortunately, no 
appropriate cell culture models are currently available for analyzing the effect of HGF on 
normal prostate epithelial differerentiation. Their high c-met expression, however, indicates 
that intermediate cells are prone to proliferation, migration and differentiation inherent to their 
putative role of amplifying cells.
Epithelial Cell Maintenance
Tissue homeostasis requires an equilibrium of cellular proliferation and apoptosis. Prostate 
epithelial basal and luminal cells reveal supplementary proliferative and apoptotic activity 
with proliferation occuring predominantly in the basal cell compartment and apoptosis in the 
luminal cell layer (39,40). The resistence of basal cells to apoptosis results at least partially 
from their high telomerase-activity and bcl-2 levels. Cell senescence is associated with 
progressive shortening of (chromosomal-) telomeres and upon a critical telomere length 
activation of the apoptotic cascade will result in cell death. Reduction in telomere length is 
prohibited by telomerase, a riboprotein complex that delays the occurrence of apoptosis by 
maintenance of telomeres; accordingly an important role in malignant transformation has 
been proposed and indeed in a number of human cancers telomerase activity is found (41). 
Within the prostate epithelium telomerase activity is high in basal cells and low in the luminal 
epithelium indicating basal cells are less accessible to apoptosis (42). While expression of the 
onco-protein bcl-2 in basal cells provides protection from apoptotic stimuli, its absence in the 
luminal epithelium predisposes exocrine and neuro-endocrine cells to undergo apoptosis 
(20,43,44).
Progression through the cell cycle requires activated complexes of cyclins and cyclin- 
dependent kinases (cdk), which can be blocked by cyclin-dependent kinase inhibitors such as 
p21/cip1/waf and p27/kip1. The cyclin-dependent kinase inhibitor p27/kip1 preferentially
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inactivates the cyclin E/cdk2 complex preventing cell cycle progression from G1 into S phase. 
Within the non-malignant prostate epithelium p27/kip1 is expressed at high levels in luminal 
cells but lacks in subgroups of basal cells and cells with a morphologically intermediate 
position in between the basal and luminal cell compartment (45). This observation 
corresponds with the exceeding proliferative activity in basal and intermediate cells, while 
most luminal cells arrive at a state of terminal differentiation (20,39,45,46).
Testosteron is the principal male androgenic hormone secreted by the testis and is 
converted into dihydrotestosteron (DHT) through the action of the enzyme 5a-reductase (47). 
DHT directly affects luminal prostate epithelium via interaction with AR, while activation of 
mesenchymal cells results in indirect growth factor release targeting respective receptors 
within the basal cell compartment (28). The dynamics of prostate epithelial maintenance have 
been investigated in castration and androgen-restoration studies in rodents and in patients who 
had undergone adjuvant androgen-deprivation for prostate carcinoma. In both models 
androgen-withdrawal results in apoptosis of luminal epithelium due to low DHT levels, while 
basal cells largely remain intact (1,2,15,48,49). A subpopulation of luminal cells, however, 
also remains viable after androgen-deprivation indicating that both basal cells and a subgroup 
of luminal cells are independent on androgens for their survival. During androgen-depletion 
the luminal prostate epithelium consists of K5-positive as well as -negative cells (49). This 
implies that phenotypically differentiated luminal cells (K8++/18++) can be subdivided into an 
androgen-dependent and -independent group. We consider the K5-negative luminal cells that 
are viable after androgen-deprivation as late intermediate cells. While enhanced proliferative 
activity of luminal epithelium during androgen-deprivation initially suggested distinct origins 
of both cell layers, in our view it rather reflects an enrichment of intermediate cells with 
proliferative activity after disappearance of post-mitotic, terminally differentiated cells 
(49,50).
Proliferative Inflammatory Atrophy
Simple atrophy and post-atrophic hyperplasia are histopathological lesions characterized by a 
decrease of luminal cell volume leading to either flat or cubical cells, respectively. 
Paradoxically, morphologic atrophy is associated with enhancement of proliferative activity 
in the luminal epithelium, but not parallelled with an increase of apoptosis (51-53). As a 
chronic inflammatory reaction frequently occurs in proximity of atrophic glands, De Marzo
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et al. proposed the term ‘Proliferative Inflammatory Atrophy’ (PIA) for these lesions (53). In 
addition to high proliferative activity and absence of p27/kip1, luminal cells in PIA express 
high levels of bcl-2 protecting them from apoptosis. The combination of enhanced luminal 
proliferative activity, unaltered apoptosis and chronic inflammation has led to the postulation 
that PIA represents a regenerative lesion.
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Figure 2. A,B Expression of K5 in human prostate epithelium Basal cells express high levels 
of K5, while luminal cells are negative (A). Intermediate cells are characterized by K5- 
expression in the luminal epithelium (B). C,D Expression of c-met in PIA and prostate 
cancer. Luminal cells in PIA express high levels of c-met. A morphologic transition to PIN, 
which is characterized by high-columnar cells with enlarged nuclei and prominent nucleoli 
can be seen (C). Scattered cells (arrow-head) in prostate adenocarcinoma express high levels 
of c-met (D).
Recently, we observed enrichement of intermediate cells (K5+/18++) within the luminal 
epithelium of PIA indicating intermediate cells have proliferative capacity. The co-expression 
of cell proliferation marker Ki-67, and absence of p27/kip1 in intermediate cells provides
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strong evidence that this cell population indeed amplifies epithelial expansion in glandular 
regeneration (Van Leenders et al., thesis chapter VI).
Irrespective of the exact role of intermediate cells, several authors suggested a 
pathogenetic link between glandular atrophy and prostate carcinoma (51-53). Glandular 
atrophy and prostate carcinoma often co-exist in the peripheral zone of the prostate, while 
PIA often shows topographic and cytonuclear transitions to Prostate Intraepithelial Neoplasia 
(PIN), the presumed precursor of prostate carcinoma (54). Figure 2. Recent demonstration of 
chromosome 8-amplifications in PIA supports a pathogenetic relation of PIA, PIN and 
adenocarcinoma (55). Although rather preliminary, these data might indicate that initial 
genetic instability is arising in highly proliferative, intermediate cells of PIA lesions. The 
occurrence of additional genetic abnormalities could subsequently transform these cells 
towards PIN and eventually progress to invasive lesions.
Intermediate Cells in Prostate Carcinoma
Prostate adenocarcinoma is characterized by a malignant transformation of luminal epithelium 
in the absence of basal cells. In spite of its presumed clonal origin, three epithelial 
subpopulations can be discriminated in prostate carcinoma. The predominant cell type 
corresponds with the exocrine, luminal epithelium expressing K8++/18++ and PSA++ (9,11-13). 
As in adenocarcinomas arising from the gastro-intestinal tract, pancreas and lung, scattered 
neuro-endocrine cells are a common finding in prostate carcinoma (18,54-58). In 1992, a third 
cell population characterized as intermediate cells (K5+/18++) was identified in prostate cancer 
(6). The focal occurrence of intermediate cells was subsequently confirmed by several groups 
in both organ-confined and disseminated prostate carcinoma (61-64). Enrichment of 
intermediate cells during androgen-deprivation and in hormone-refractory prostate carcinoma 
indicates that these are independent on androgens for their survival (63,64). The physiology 
of androgen-independent neuro-endocrine cells in prostate carcinoma seems more complex. 
While the occurrence of neuro-endocrine cells can be explained by according differentiation 
of malignant progenitor cells, androgen-deprivation and stimulation with Epi, Fsk, Interleukin 
(IL)-1 or IL-6 are able to induce reversible neuro-endocrine differentiation in the androgen- 
dependent prostate cancer cell line LNCaP (65-67). Apparently, even malignant cells with an 
advanced state of exocrine differentiation have the capacity to switch towards an androgen­
independent neuro-endocrine phenotype.
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In agreement with the stem cell concept of Isaacs and Coffey, the intermediate cell type has 
been postulated as the progenitor cell of malignant transformation in the prostate epithelium 
(3,6,19,50,68). First, intermediate cells are regarded as multipotential progenitor cells which 
can either mature towards an exocrine or neuro-endocrine phenotype explaining cellular 
heterogeneity in a clonal disease, while putative stem cells (K5++/14++/18+) are absent in 
prostate carcinoma (19). Furthermore, topographic and morphologic transition of PIA lesions, 
enriched for intermediate cells, with PIN suggests a role of intermediate cells in prostate 
carcinogenesis, which is supported by the amplification of chromosome 8 in this process 
(54,55). The presence of proliferative intermediate cells which seem resistant to apoptosis by 
their expression of bcl-2 in a background of chronic inflammation might sensitize this cell 
population for gain of genetic abnormalities (53). Thirdly, intermediate cells highly express 
the c-met receptor in normal and malignant prostate epithelium (50). Co-transfection of HGF 
and c-met leads to malignant transformation of NIH3T3 cells (69,70). Activation of c-met in 
prostate cancer cell line DU145 enhances its invasive capacity (38,71). Furthermore, 
intermediate cells in prostate carcinoma co-localize a2-integrin (Van Leenders et al., thesis 
chapter VII). Expression of a2p1-integrin mediates invasion and metastatic dissemination in 
gastric, breast, ovarian and oral carcinoma models (72-75). Accordingly, the expression of a2- 
integrin in prostate carcinoma suggests altered matrix-adhesion at the level of intermediate 
cells, resulting in enhanced invasive capacity of this specific cell population. Altogether, these 
data suggest that intermediate cells are prone to malignant transformation upon continuous c- 
met activation.
Potential Therapeutic Implications
Interestingly, molecular characterization of intermediate cells brings forth potential targets for 
prostate cancer therapy. At this moment several interesting pathways exist for interception 
with intermediate cells in prostate carcinoma based on their presumed tyrosine kinase receptor 
expression. Preliminary cell culture studies have indicated that prostate cancer invasion is 
suppressed by the HGF variant NK4 (76). The ATP analog K252a is a potent inhibitor of 
tyrosine kinases of the Trk-family but also inhibits autophosphorylation of c-met resulting in 
reversal of NIH3T3 fibroblasts transformed by c-met (77). While the cellular expression of 
tyrosine kinase receptors EGFR and HER-2/neu in prostate cancer remains to be elucidated, 
both are currently on trial for treatment of malignancies. The expression pattern of both 
EGFR and HER-2/neu in intact basal prostate epithelial cells as well as androgen-deprived
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prostate carcinoma might be explained by their localization in intermediate cells (63,78-81). 
Pharmacological inhibitors and antibodies directed to EGFR form another promising 
approach for the treatment of prostate carcinoma, and are currently validated in patients with 
prostate cancer (82,83). Although HER-2/neu inhibition seems effective in breast cancer 
therapy, its merit in the treatment of prostate carcinoma is not resolved yet as methodologic 
selection of patients with HER-2/neu over-expression is controversial (81,84-86).
Figure 3. Epithelial cell model for prostate carcinogenesis. Intermediate cells (K5+/18++) are 
target cells for malignant transformation of the prostate epithelium, retaining their capacity 
to show either exocrine (upper lineage) or neuro-endocrine (lower lineage) differentiation. 
The final step of terminal, exocrine differentiation is believed to be dependent on androgens 
(left). In androgen-independent prostate cancer, terminal exocrine differentiation is 
diminished, leading to a relatively increased number of intermediate and neuro-endocrine 
cells (right).
During androgen-deprivation for disseminated prostate carcinoma the majority of terminally 
differentiated, exocrine cells undergo apoptosis, while subpopulations of intermediate and 
neuro-endocrine cells remain viable (63,64,87). Expansion of androgen-independent 
intermediate cells with less advanced exocrine differentiation possibly combined with cell- 
cycle re-enterance of neuro-endocrine cells might result in hormone-refractory prostate cancer 
progression despite low androgen-levels (66). Figure 3. Evidence is accumulating that the 
AR-mediated pathways are still activated in prostate cancer, albeit in a ligand independent 
manner (88). Recruitment of signalling pathways that finally integrate with the AR signalling
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provides a molecular explanation for androgen-independent prostate cancer progression. 
Targeting intermediate cells as presumed progenitors of prostate carcinogenesis by inhibition 
of their AR-intercepting pathways offers new opportunities in the treatment of prostate 
cancer.
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Summary
Prostate cancer is the most common malignancy among western men. Radical prostatectomy 
is currently the standard treatment for organ-confined disease. Prostate cancer is characterized 
by its androgen-sensitivity, and therapeutic withdrawal of androgens is widely applied for 
metastasized prostate cancer. Although androgen-deprivation initially leads to tumour- 
regression, most patients eventually experience androgen-independent recurrences in spite of 
low androgen levels. At this moment no satisfactory therapeutic options are available for the 
treatment of hormone-escaped prostate cancer. In spite of its incidence and well-known 
clinical course, the cell types involved in prostate carcinogenesis and responsible for 
hormone-refractory disease are poorly understood.
The normal human prostate epithelium is composed of luminal exocrine cells, 
scattered neuro-endocrine cells and basal cells that might represent stem cells of the entire 
prostate epithelium (Chapter I). Three cell populations are discriminated in prostate 
carcinoma. Luminal secretory cells (1) predominate in prostate carcinoma, while scattered 
neuro-endocrine cells (2) are also present. Although it was generally believed that prostate 
cancer lacked basal cells, a cell population immunophentypically intermediate in basal and 
luminal cells (3) could be identified in normal as well as malignant prostate epithelium. In 
accordance with their putative role of progenitor cells in normal prostate epithelial 
differentiation, several groups hypothesized intermediate cells as precursors of prostate 
carcinogenesis and targets of androgen-independent prostate cancer progression. This thesis 
analyses the cell biological characteristics of intermediate cells in normal prostate epithelium 
and prostate cancer (Chapter II).
The study of intermediate cells has been hampered by lack of a methodology in which 
intermediate cells can be recognized in vivo and in vitro. The development of a 
immunofluorescent triple-staining using directly fluorochrome-labelled antibodies directed 
towards keratins (K) allowed the identification of four epithelial subpopulations in the human 
prostate epithelium (Chapter III). While the basal cell compartment consists of 
K5++/14++/18+- and K5++/14"/18+-positive cells, luminal epithelial cells are either 
characterized by expression of K5+/14718++ or K5714718++. Accordingly, characterization of 
primary cell cultures further revealed that subsets of basal cells (K5++/14++/18+) are progenitor 
cells of K5/18-positive cells and differentiated epithelium (K5714718++). This indicates the 
existence of a hierarchic stem cell concept in which the entire prostate epithelium is derived 
from a single stem cell population.
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Separate immunohistochemical evaluation of K5-, K14- and K18- expression further 
demonstrated the existence of intermediate cells (K5/18) in 28.9% of prostate cancer 
metastases, while the putative stem cell population is completely absent (Chapter IV). The 
number of metastases harbouring intermediate cells increased to 57.1% in hormone-refractory 
disease, which was combined with an increase in the number of intermediate cells within each 
tumour. The association of intermediate cells with androgen-independent prostate cancer was 
reflected in the immunophentype of prostate cancer cell lines. The androgen-dependent cell 
line LNCaP resembled differentiated luminal epithelium (K18++), while both androgen­
independent DU145 and PC3 had an intermediate phenotype (K5/18). Hence, intermediate 
cells seem androgen-independent for their survival in prostate cancer.
Expression of “basal cell markers” within the luminal prostate epithelium is 
characteristic for the intermediate cell population. The Hepatocyte Growth Factor receptor c- 
met is involved in tissue regeneration and morphogenesis, which both result from coordinated 
cell proliferation, migration and differentiation. Intermediate cells in normal and malignant 
prostate epithelium highly express the receptor c-met, supporting their role as amplifying cell 
in prostate epithelial differentiation (Chapter V). The increase of c-met expression in 
hormone-regressed prostate cancer confirmed the presumed androgen-independent nature of 
these cells. Stimulation of DU145 with HGF resulted in scattering and increased invasive 
capacity of this cell line, raising the question whether intermediate cells are prone to stromal 
invasion in prostate cancer.
Glandular atrophy is a frequent histological finding in prostate specimens, which is 
often associated with inflammation. Despite its morphological appearance and nomenclature, 
atrophic epithelium paradoxically has an increased proliferative activity but a similar 
apoptotic rate, as compared to high-columnar luminal epithelium. These lesions, currently 
termed “Proliferative Inflammatory Atrophy” (PIA), are highly enriched for intermediate cells 
within their luminal epithelium, as indicated by increase of K5- and c-met-expression 
(Chapter VI). Therefore, PIA lesions offer a morphological substrate for the study of 
intermediate cells. The expression of proliferation marker Ki-67 and absence of the cell-cycle 
dependent kinase inhibitor p27/kip1 shows that intermediate cells have proliferative capacity 
and modulate regenerative prostate epithelium.
To gain further insight in the role of c-met expression in intermediate cells, the gene­
expression profile of DU145 was analysed after HGF stimulation. Although both a2-integrin 
and laminin-y2 mRNA were increased by c-met activation, this was reflected by enhanced 
a2-integrin protein expression only (Chapter VII). Co-localization studies confirmed the
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expression of a2-integrin in intermediate cells in normal and malignant prostate epithelium. 
As a2-integrin is expressed at the invasive fronts of various epithelial malignancies, we 
hypothesize that intermediate cells play a prominent role in prostate cancer invasion.
The putative important biological role of intermediate cells in prostate carcinogenesis 
and androgen-escape has important implications for the treatment of prostate cancer. Instead 
of targeting androgen-dependent differentiated cells, therapeutic disruption of intermediate 
cells might fundamentally participate in the treatment of prostate cancer. Their expression of 
tyrosine-kinase growth factor receptors, such as c-met, offers pharmacological targets for the 
elimination of intermediate cells in prostate cancer (Chapter VIII).
Samenvatting
Prostaatkanker is de meeste voorkomende kwaadaardige tumor (maligniteit) onder westerse 
mannen. Chirurgische verwijdering van de prostaat is de standaard behandeling voor 
prostaatkanker, als deze zich niet buiten het orgaan uitbreidt. Prostaatkanker wordt 
gekenmerkt door zijn gevoeligheid voor androgenen, zoals testosteron, hetgeen de rationale 
vormt voor de behandeling van uitgezaaide (gemetastaseerde) tumoren. Hoewel 
therapeutische androgeen-blokkade in het begin leidt tot tumorregressie, keert de tumor bij de 
meeste patiënten terug (recidief) ondanks lage androgeen-spiegels. Er zijn op dit moment 
geen goede behandelingsmogelijkheden voor de androgeen-onafhankelijke progressie van 
prostaatkanker. Ondanks het frequente voorkomen en ongunstige klinische beloop van 
prostaatkanker is er weinig bekend over de celtypen, die betrokken zijn bij het ontstaan van 
prostaatkanker en verantwoordelijk kunnen worden gehouden voor hormoon-onafhankelijke 
tumorprogressie.
De klierbuizen in de normale prostaat worden bekleed door twee epitheliale cellagen. 
De buitenste, luminale cellaag scheidt eiwitten uit in de klierbuizen, terwijl verspreid neuro- 
endocriene cellen voorkomen, die waarschijnlijk het biologische gedrag van naburige cellen 
kunnen beïnvloeden. De binnenste, basale cellaag vertegenwoordigt mogelijk de stamcel 
populatie, die fungeert als voorlopercel van het gehele prostaat epitheel (Hoofdstuk I). In 
prostaatkanker worden drie celpopulaties aangetroffen. Het meest voorkomende celtype is de 
luminale cel, terwijl verspreid ook neuro-endocriene cellen aanwezig zijn. Hoewel over het 
algemeen wordt aangenomen, dat basale cellen afwezig zijn in prostaatkanker, komt een 
derde celgroep met intermediaire kenmerken van zowel basale als luminale cellen voor in
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normaal en kwaadaardig prostaatepitheel. In overeenstemming met hun vermeende rol als 
voorlopercel van het normale prostaat epitheel, postuleren verschillende onderzoeksgroepen, 
dat zowel de kwaadaardige ontaarding van de prostaat als de androgeen-onafhankelijke 
prostaatkanker progressie uitgaat van intermediaire cellen. In dit proefschrift worden de 
biologische eigenschappen van intermediaire cellen in normaal en kwaadaardig 
prostaatepitheel bestudeerd (Hoofdstuk II).
De studie van intermediaire cellen wordt bemoeilijkt door het gebrek aan een 
methode, die intermediaire cellen herkent in prostaatweefsel en celkweek. Door de 
ontwikkeling van een immunfluorescente triple-kleuring gebruikmakend van direct gelabelde 
antilichamen tegen bepaalde celskelet eiwitten (keratines; K) werden vier celpopulaties 
onderscheiden in de normale prostaat (Hoofdstuk III). Terwijl het basale compartiment 
bestaat uit K5++/14++/18+- en K5++/14-/18+-positieve cellen, vertonen luminale cellen 
expressie van K5+/14-/18++ danwel K5714718++. Karakterisatie van primaire celkweken van 
prostaatepitheel wijst verder uit, dat een subset van basale cellen (K5++/14++/18+) voorlopers 
zijn van intermediaire (K5/18) en uitgerijpte cellen (K5714718++). Dit duidt op het bestaan 
van een hiërarchisch stamcelconcept, waarbij het gehele prostaatepitheel ontstaat uit een 
enkele stamcelpopulatie.
Afzonderlijke immunohistochemische evaluatie van K5-, K14- en K18- expressie 
toont aan, dat in 28.9% van de prostaatkanker metastasen intermediaire cellen (K5/18) 
voorkomen, terwijl de vermeende stamcel afwezig is (Hoofdstuk IV). Het aantal metastasen 
met intermediaire cellen neemt toe tot 57.1% bij hormoon-onafhankelijke progressie, tegelijk 
met het aantal cellen, dat per tumor gevonden wordt. De associatie van intermediaire cellen 
met androgeen-onafhankelijk prostaatkanker wordt weerspiegeld in het immunophenotype 
van prostaatkanker cellijnen. De androgeen-afhankelijk cellijn LNCaP gelijkt op uitgerijpt 
luminaal epitheel (K18++), terwijl de androgeen-onafhankelijke DU145 en PC3 intermediaire 
kenmerken vertonen (K5/18). Derhalve lijken intermediaire cellen onafhankelijk van 
androgenen voor hun overleving.
Expressie van “basale cel kenmerken” in luminaal epitheel is karakteristiek voor de 
intermediaire celpopulatie in de prostaat. De Hepatocyte Growth Factor (HGF) receptor c-met 
is betrokken bij gecoördineerde proliferatie, migratie en differentiatie, welke noodzakelijk 
zijn bij weefselreparatie en morphogenesis. Intermediaire cellen in zowel normaal als 
kwaadaardig prostaatepitheel brengen de c-met receptor sterk tot expressie, hetgeen hun 
functie van zogenaamde amplificerende cel ondersteunt (Hoofdstuk V). De toename van c- 
met expressie in prostaatweefsel tijdens androgeen-blokkade bevestigt de androgeen-
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onafhankelijk aard van intermediaire cellen. Daar stimulatie van DU145 met HGF resulteert 
in celspreiding en toename van invasieve capaciteit, lijkt het mogelijk, dat intermediaire 
cellen betrokken zijn bij tumorinvasie in het omgevende prostaatweefsel.
Klierbuisatrofie is een veel voorkomende bevinding in prostaatweefsel, welke vaak 
gepaard gaat met lokale chronische ontsteking. Ondanks dit morphologisch aspect en de 
hierbij passende nomenclatuur, is er paradoxaal een toegenomen celproliferatie in atrofisch 
epitheel in vergelijking met normaal uitgerijpt epitheel. Deze afwijking, welke aangeduid 
wordt als “Proliferative Inflammatory Atrophy” (PIA) bevat een sterk toegenomen aantal 
intermediaire cellen in de luminale cellaag, zoals blijkt uit de expressie van K5 en c-met 
(Hoofdstuk VI). PIA lesies vormen aldus een morphologisch substraat voor de verdere 
bestudering van intermediaire cellen. De expressie van proliferatiemarker Ki-67 toont aan, dat 
intermediaire cellen inderdaad celdeling ondergaan en dientengevolge weefselhomeostatse 
kunnen moduleren.
Ter detectie van nieuwe potientiële markers voor intermediaire cellen, werd het gen­
expressie patroon van DU145 na HGF stimulatie geanalyseerd. Hoewel zowel a2-integrin als 
laminin-y2 mRNA toeneemt na c-met activatie, volgt alleen translatie naar een verhoogde a2- 
integrin eiwit expressie (Hoofdstuk VII). Co-lokalisatie studies bevestigen de expressie van 
a2-integrin in intermediaire cellen van zowel normaal als kwaadaardig prostaatepitheel. 
Gezien a2-integrin met name tot expressie komt in het invasieve front van verschillende 
epitheliale kwaadaardige gezwellen, postuleren wij, dat intermediaire cellen een prominente 
rol spelen bij prostaatkankerinvasie.
De vermeende biologische betekenis van intermediaire cellen bij het ontstaan van 
prostaatkanker en diens androgeen-onafhankelijke progressie heeft belangrijke consequenties 
voor de behandeling van deze ziekte. In het licht hiervan zou de behandeling van 
prostaatkanker namelijk vooral gericht dienen te zijn op de intermediaire celpopulatie in 
plaats van de uitgerijpte androgeen-afhankelijke cellen. De expressie van groeifactor 
receptoren, zoals c-met, in intermediaire cellen kan bijvoorbeeld dienen als een nieuw 
therapeutisch aangrijpingspunt bij de behandeling van prostaatkanker (Hoofdstuk VIII).
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Chapter I: Figure 1 (page 10)
Keratin expression discriminates four distinct cell populations within the human prostate 
epithelium. Luminal cells either express K18++ (green) or K5+/18++ (yellow), while basal cells 
are characterized by co-localization of K5++/14++/18+ (pink/ purple) or K5++/18+ (red). K5: 
Alexa 546 (red). K18: Alexa 488 (green). K14: Cy5 (blue). Hybrid colours: K5/14 (purple), 
K5/18 (red-yellow). CLSM.
Chapter III : Figure 1 (page 30)
Keratin expression in normal prostate epithelium. A Luminal cells strongly express K18 
(K18++; green signal) and focally show co-expression of K5 and 18 (K5+/18++; hybrid yellow 
signal). Two cell populations are discriminated in the basal cell layer. All basal cells show 
strong expression of K5 and are weakly positive for K18, only detectable at higher sensitivity 
levels of the scanning microscope (K5++/18+; red signal). Co-localization of K5, 14 and 18 
(K5++/14++/18+; hybrid purple signal) is encountered in a subpopulation of basal cells. B  At 
higher detection level K18 is demonstrated in all basal cells. Co-localization of K5 and 18 in 
basal cells is shown by a hybrid yellow signal (K5++/18+) and co-expression of K5, 14 and 18 
by a white signal (K5++/14++/18+). K5: Alexa 546 (red). K18: Alexa 488 (green). K14: Cy5 
(blue). Arrows point out hybrid signals: red K5++/18+, purple K5++/14++/18+, yellow K5+/18++. 
CLSM.
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Chapter III: Figure 3 (page 31)
Keratin expression in epithelial cell culture. Three distinct epithelial cell types are found in 
monolayer culture. A Most epithelial cells are strongly positive for K5 and 14, while they 
show weak expression of K18 (K5++/14++/18+; white asterisk). Expression of K14 is decreased 
in a subpopulation of epithelial cells (red asterisk) and sporadically absent (K5++/18+; yellow 
asterisk). B,C Some cells express high levels of K18 (K5+/14+/18++). These cells either have 
an angular shape (B), or reveal several cytoplasmic extensions (C). The latter cell type is also 
encountered on top of the monolayer. CLSM.
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Chapter III : Figure 4 (page 31)
Differentiation in gland-like buds after confluence of cell cultures. Gland-like buds and 
extensions have a complex cell composition. Cells with a basal phenotype (K5++/14++/18+; 
hybrid purple signal) cover the gland-like buds. Differentiation towards a luminal phenotype 
is found in the centre of the gland-like buds. These cells strongly express K18 (K18++; green 
signal). CLSM.
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Chapter IV : Figure 3 (page 45)
Keratin expression in prostate cancer cell lines. A LNCaP expresses K18 (green) without K5 
or 14. B  K5 and K18 are both expressed in DU145 in the absence of K14 (hybrid yellow). 
Some cells reveal low K5 expression, identified by a green rather than a yellow signal. C PC3 
is homogeneously positive for K5 and 18 without expression of K14 (hybrid yellow colour). 
K5: Alexa 546 (red). K18: Alexa 488 (green). K14: Cy5 (blue). Co-localization of K5/18: 
yellow colour. CLSM.
Chapter V: Figure 3 (page 59)
Localization of c-met in non-malignant prostate epithelium (A) and prostate carcinoma (B) 
using immunofluorescent triple-staining combining K18, K5 and c-met. In normal luminal 
prostate epithelium, differentiated cells (K18++) lack c-met expression, while intermediate 
cells characterized by co-localization of K5 and K18 (K5+/18+ ) display high c-met levels. 
The receptor c-met is also found in K5 expressing basal cells. In prostate carcinoma, c-met is 
highly expressed in intermediate cells (K5+/18++). Differentiated prostate cancer cells (K18++) 
reveal low c-met levels. K5: Alexa 546 (red). K18: Alexa 488 (green). c-met. Cy5 (blue). Co­
localization K5/18/c-me£ hybrid white/ purple. CLSM.
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Chapter VI:Figure 1 (page Z2)
Morphological and K5 phenotype of PIA. A Region of simple atrophy. Arrows indicate 
normal appearing epithelium with abundant clear cytoplasm. Note basophilic appearance of 
the majority of the acini. B  High power image of area indicated in boxed region in A. Note 
two cell layers consisting of cubical and basophilic luminal cells (arrowheads) and darker 
underlying basal cells (arrows). C Normal appearing epithelium (n) and PIA stained with anti- 
K5 antibodies. Note strong staining of basal layer in all epithelia, lack of staining of luminal 
cells in normal acini, and weak but positive staining in many of the luminal cells in atrophic 
acini. D  Higher power view of an atrophic acinus from C. Arrowheads indicate luminal 
secretory cells and arrows indicate basal cells.
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Chapter VI: Figure 3 (page 74)
Immunoflourscence double-labelling of PIA. Upper panel demonstrates Ki-67 (arrow) 
expression in K5-positive intermediate luminal cells. Note basal layer showing strong K5 
staining and weaker but positive K5 staining in the majority of luminal cells. High power 
view from another area of PIA showing Ki-67 positive luminal cell (right). Lower panel 
shows strong staining for p27/kip1 in the vast majority of columnar luminal secretory cells in 
a normal acinus (left). Area of PIA without p27/kip1 staining in a group of K5-positive 
luminal cells (right; arrows). L indicates lumen, S indicates stroma.
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Chapter VII: Figure 2 (page 89)
a2-Integrin protein is over-expressed in DU145 cells stimulated with HGF. A, B 
Immunofluorescent staining of a2-integrin (red) in control cells (A) and after stimulation with 
25 ng/ml HGF for 24 hours (B). a2-Integrin: Alexa 594 (red). c-met. Alexa 488 (green). 
CLSM. FACS-analysis demonstrates a shift in DU145 cells after HGF stimulation 
corresponding with their enhanced membranous a2-integrin expression (control: dotted line, 
HGF-treated: straight line).
Chapter VII: Figure 4 (page 91)
Expression of laminin-y2 and a2-integrin within the prostate epithelium. A laminin-y2 is 
expressed in the basement membrane, but not in intermediate, K5 expressing luminal cells. B 
Co-localization of a2-integrin and K5 in intermediate cells of the luminal epithelium. 
Laminin-y2 (A) and a2-integrin (B): Alexa 488 (green). K5: Alexa 546 (red). Nuclei: TO- 
PRO (blue). CLSM.
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Chapter VII: Figure 5 (page 91)
Expression of a2-integrin in intermediate cells within prostate carcinoma. Intermediate cells 
are characterized by K5 expression (arrow-heads). A a2-Integrin: Alexa 488 (green). B  K5: 
Alexa 546 (red). C Nuclei: TO-PRO (blue). D  Triple-labelling a2-integrin, K5 and nuclei. 
CLSM.
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